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1   Abstract 
Receptor tyrosine kinases (RTKs) activate the mitogen-activated protein (MAP) kinases 
called extracellular signal-regulated kinases 1 and 2 (ERK1/2) through a signaling cascade 
involving proteins such as Shc, Grb2, SOS, Ras, Raf-1 and MEK. Activation of ERK1/2 
directs proliferation and differentiation in a wide array of cell types. G-protein-coupled 
receptors (GPCRs) of many types have been shown to activate the ERK cascade, but the 
complete mechanisms are yet to be elucidated. Gs-coupled receptors activate adenylyl 
cyclase (AC) leading to a rapid increase in cyclic AMP (cAMP), and the main targets for 
cAMP are protein kinase A (PKA) and the Exchange Protein directly Activated by cAMP 
(Epac) specific for the small G-protein Rap1. It has been proposed for the Gs-coupled β2-
adrenergic receptor that activation of ERK1/2 proceeds through Rap1 and B-Raf in a 
manner independent of Ras. However, for the human Gs-coupled serotonin receptors 5-
HT4(b) and 5-HT7(a) it has been shown that ERK1/2 activation occurs independently of 
Rap1, relying instead on PKA and Ras. 
   In this project we have explored various signaling mechanisms originating from the 
human Gs-coupled 5-HT7 serotonin receptors, with particular interest in the mechanisms of 
activation of ERK1/2. 
   We demonstrate the activation of ERK1/2 in HEK293 cells transfected with 5-HT7(b) and 
5-HT7(d) receptors subsequent to stimulation with serotonin. For the 5-HT7(b) receptors, we 
show that the observed activation of ERK1/2 is dependent on cAMP and Ras, but not on 
Epac and Rap1. Furthermore, direct cytosolic calcium measurements have shown that 
treatment with serotonin leads to a rapid but transient elevation in intracellular calcium in 
HEK293 cells stably transfected with 5-HT7(b) receptors, and the observed phosphorylation 
of ERK1/2 is mediated, at least partly, through a calcium-dependent pathway. We show 
that HEK293 cells endogenously express the Ras specific, Ca2+/calmodulin-dependent 
guanine nucleotide exchange factor Ras-GRF1. Ras-GRF1 becomes phosphorylated 
subsequent to 5-HT stimulation of 5-HT7(b) receptors, and it has previously been 
demonstrated that this phosphorylation enhances its towards Ras. This indicates that Ras-
GRF1 has a role in the observed Ras-dependent activation of ERK1/2 mediated through 5-
HT7(b) receptors.   
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2   Introduction 
2.1   Cell Signaling 
In a complex cellular arrangement like that of the human body, the ability of cell 
communication is of paramount importance. The cells exist and function exclusively for the 
benefit of the whole organism, and they must work together so as to direct and synchronize 
cellular functions. All of this relies on proper cellular signaling. Neuronal and 
endocrine/paracrine signaling are the two main strategies employed for this to be 
accomplished. These depend on and complement each other’s role in the human cell 
system, and neither can be said to be more important than the other. Whereas neuronal 
signaling implies very direct and precise manipulation of target organs, (i.e. muscles, the 
adrenal medulla, the heart, the kidneys etc.) endocrine/paracrine signaling is much broader 
and slower, but may still affect the same tissues as neurons do.  
   Common for both of these methods is the utilization of chemical substances that bind to 
corresponding receptors, which then convey signals into the cells and direct cellular 
behavior. Neurons release neurotransmitters in the synaptic cleft, the 2 nm gap between 
itself and a target cell, and is consequently a very direct and clear-cut signal originating 
straight from the central or enteric nervous systems.  
   Other cells discharge mediators directly into the extracellular fluids surrounding them, 
and this constitutes a less discrete signal, but still just as important. Depending on the 
stability of these chemicals the signal can be classified as of endocrine or paracrine 
character. Hormones are examples of the former, and they are typically released by 
specialized glands into the blood stream from where they have access to the whole body 
through the circulation of the blood. Paracrine signals on the other hand are employed by 
all the cells in the body and function only in the near vicinity of the source, or even on the 
source itself (autocrine signaling). An instructive example of paracrine signals is found in 
the immune system with the plethora of cytokines these cells utilize to coordinate the 
body’s immunological response to microbial infections. 
   An important aspect and common to all signaling mediators, is that they only affect cells 
displaying the proper receptors. Each cell in the human body produces a specific variety of 
receptors, and together they constitute an important part of the cell’s identity, which is to 
say, its function and role in the cellular society. The same signaling molecule may also bind 
to receptors of different classes, so the combination of different signals reaching a cell, and 
the particular receptors it displays, determines its fate in the organism – proliferation, 
differentiation, movement, gene expression or apoptosis. 
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2.1.1   Cell receptors 
Two main classes of receptors are present in the cell, those localized intracellularly and 
those embedded in the plasma membrane. Intracellular receptors are targets of lipophilic 
substances which cross the plasma membrane directly (e.g. steroid hormones and thyroid 
hormones). Such receptors are often gene regulatory proteins or in close proximity in 
signaling cascades to such, and their main function is to regulate the transcription of genes, 
either by induction or inhibition. 
   Plasma membrane receptors (table 2.1) on the other hand transmit signals from 
extracellular hydrophilic substances into the cell via an array of intracellular signaling 
molecules (also known as a signaling cascade). Plasma membrane receptors constitute a 
group of three main types, and these are: Enzyme-linked receptors, ligand gated ion 
channel and last but not least, G-protein coupled receptors (GPCRs). The latter is by far the 
most predominant and diverse. Common for all transmambrane receptors is an extracellular 
N-terminal domain to which the ligand binds, a transmembrane domain usually composed 
of α-helices and an intracellular C-terminal domain which conveys the signal to proteins 
inside the cell. 
 
 
 
Table 2.1   Examples of plasma membrane receptors and their ligands 
 Ligand Receptors 
Epithel growth factor (EGF) EGFR 
Platelet derived growth factor (PDGF) PDGFR 
Insulin-like growth factor (IGF) IGFR 
Transforming Growth Factor β (TGF- β) TGF-β receptor 
Enzyme linked 
Atrial Natriuretic Peptide (ANP) ANP receptor 
Acetylcholine Nicotinergic 
Serotonin (5-HT) 5-HT3 
Gamma-aminobutyric acid (GABA) GABAa receptor 
Glutamate GluR channel, NMDA 
Ion channel 
Glycine NMDA 
Acetylcholine (ACh) Muscarinergic (M1-M5) 
Serotonin (5-HT) 5-HT receptors (5-HT1, 2, 4-7) 
Catcholamines (NA) Adrenergic (α1-2, β1-3) 
Histamine (H) Histaminergic (H1-H2) 
G protein-coupled 
Dopamine (DA) Dopaminergic (D1-D5) 
 
 
The enzyme-linked receptors consist of five main classes, each with considerable 
heterogeneity: Receptor tyrosine kinases are polypeptides with single transmembrane 
segments that form either hetero- or homo-dimers upon ligand binding. The receptors are 
activated by autophosphorylation on several tyrosine residues which subsequently may 
result in binding of proteins that direct signals into the cell. The other classes are receptor 
serine/threonine kinases (TGF-β receptor), receptor guanylyl cyclases (ANP receptor), 
tyrosine kinase associated receptors (cytokine receptors) and receptor-like tyrosine 
phosphatases (CD45). 
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The ligand gated ion channels usually consist of several transmembrane α-helices 
arranged in a way so that they form a pore with a specific diameter through which 
particular ions may pass (Na+, K+,Ca2+, or Cl-.) The extracellular side has binding sites for 
signaling molecules which after binding propagate a conformational change in the receptor 
which opens the pore, thus allowing the flow of ions from one side of the plasma 
membrane to the other. Ligand gated ion channels are typically situated in post synaptic 
membrane of the synapses between neurons or a target cell. The neurotransmitters released 
by the synapse operate as ligands for the receptor, and an excitatory or inhibitory signal is 
passed on to the postsynaptic cell, depending on what ion the receptor conducts. 
 
2.2   G-Protein-Coupled Receptors (GPCRs) 
G-Protein coupled receptors, also known as seven transmembrane segment receptors 
(7TMRs), heptahelical or serpentine receptors, is a group consisting of more than 2000 
members, compromising >6% of the human genome. Over 100 subfamilies have been 
defined according to sequence homology, ligand structure and receptor function (1). 
GPCRs thus make up the largest and most diverse superfamily of proteins in the whole 
human body and since the cloning of the β2-adrenergic receptor (β2-AR) for catecholamines 
in 1986 (2), extensive experimental work has been elicited to uncover the variety of their 
functions. 
   Ligands for the GPCR group include many small chemical molecules, nucleotides, 
nucleosides, peptides, lipids, proteins, hormones, neurotransmitters, pheromones as well as 
retinal, the light activated ligand of rhodopsin. The importance of GPCRs can be 
envisioned by the fact that more than 60% of the drugs utilized today have these receptors 
as their targets, either directly or indirectly. There is still much work to be done before we 
understand completely the physiological, biochemical, pathological and pharmacological 
backgrounds of these complex signaling networks.  
 
2.2.1   The basic structure of GPCRs 
On the level of primary and secondary structure, much 
information is available since many GPCRs have been 
sequenced and cloned. Overall, these receptors do not share 
much amino acid homology and the only structural feature 
common to all GPCRs is the presence of the seven 
transmembrane (TM) spanning α-helical segments connected 
by alternating intracellular and extracellular loops, with the 
amino terminus located on the extracellular side and the 
carboxyl terminus on the intracellular side (fig. 2.1). The 
transmembrane segments cluster in the membrane and play a 
vital part in ligand binding and transduction of the signal into 
the cell. The α-helices are termed transmembrane 1 (TM1) 
through transmembrane 7 (TM7) starting at the N-terminal 
end. Three extracellular and three intracellular loops are 
formed between the TM segments. In some GPCRs, a fourth 
intracellular loop is formed when a part of the C-terminal tail is palmitoylated at a cysteine 
Figure 2.1   The basic structure 
of GPCRs. 
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residue and anchored to the plasma membrane. The 
extracellular loops and the N-terminus play a role in ligand 
binding whereas the intracellular loops and the C-terminus are 
involved in interaction with G proteins (see chapter 2.2.3). 
Each of the seven α-helices is composed of 20-27 hydrophobic 
amino acids. The N-terminal and C-terminal segments, as well 
as the intracellular and extracellular loops vary considerably in 
length (5-600 amino acids) indicating a diversity of functions. 
      Based on marginal sequence similarities, three major 
families and several subfamilies of GPCRs have been 
defined (table 2.2). Sequences within each family generally 
share over 25% identity in the transmembrane core regions. 
The family A receptors are by far the best studied, and share 
some conserved key residues thought important for structural and functional integrity (The 
DRY (Asp-Arg-Tyr) motif in the third intracellular loop being the prime example). For the 
family B receptors, the most prominent feature is a large (~100 amino acids) extracellular 
N-terminus, containing several cysteines, probably involved in forming a network of 
disulphide bridges. Family C receptors are characterized by very large N-termini (500-600 
amino acids) thought to play a role for agonist binding. 
 
Table 2.2   Various G protein-coupled receptor families 
Family Receptors 
A Rhodopsin/ 
β2-AR family 
Receptors for adrenaline, serotonin, dopamine, acetylcholine, 
histamine, endothelin, bradykinin, adenosine, cannabinoids, 
eicosanoids, chemokines, opioides, vasopressin, oxytocin, 
and many more. 
B Glucagon 
receptor family 
~25 members. Peptide hormones and neuropeptides 
(Glucagon, secretin, VIP, calcitonin, GHRH, CRH and 
PTH). 
C Metabotropic 
neurotransmitter 
receptors 
Glutamate, GABA, Ca2+, pheromone and taste receptors. 
 
2.2.2   Function of GPCRs 
2.2.2.1   Basic agonist binding and signal transduction theory 
G-protein-coupled receptor signaling is made up of three distinct molecular components: 
discriminators (receptors), transducers (G-proteins), and amplifiers (effectors). Simply 
stated, the discriminator, the GPCR, is stimulated by its specific extracellular ligand. 
Agonist binding occurs by several mechanisms, for example: binding within a hydrophobic 
ligand pocket formed by the seven TM spanning domains (family A), binding to the 
extracellular loop domains and the amino-terminal tail of the receptor (family B) or binding 
to a stretch of amino acids within the long extracellular amino-terminal tail (family C). 
   Agonist binding leads to a conformational change in the receptor, allowing it to recruit 
specific heterotrimeric G-proteins – the transducers. They in turn convey the signal to 
Figure 2.2   The alignment of 
transmembrane segments in the 
plasma membrane seen from the 
extracellular side. 
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intracellular amplifiers as described in the next chapter. The current theory explaining 
GPCR activity suggests that the GPCRs can spontaneously isomerize between inactive and 
activated receptor conformations leading to the non-agonist induced activation of G-
proteins. Consequently, GPCRs exhibit some degree of spontaneous constitutive activity in 
the absence of agonist stimulation. Receptor activation by agonists merely promotes the 
stabilization of the activated receptor conformation, thereby potentiating interaction with G 
proteins (3).    
   Inverse agonists are drugs that do not stimulate receptor activation but rather selectively 
recognize or stabilize the inactive receptor conformation and thereby reduce the 
spontaneous or intrinsic activity of GPCRs. Full antagonists do not preferentially recognize 
or stabilize either the inactive or active receptor conformation but competes with agonists 
for receptor binding. Thus, the treatment of cells with full antagonists will result in no net 
change in receptor activity in the absence of agonists; rather, the antagonists will block the 
activity of both customary agonists and inverse agonists if they are present. Inverse agonists 
on the other hand, have the ability to abolish the receptor’s intrinsic activity. 
 
2.2.3   G-proteins 
G-proteins are so-called because they bind the guanine nucleotides GDP and GTP. They are 
activated by the exchange of GDP for GTP, and subsequently inactivated by the hydrolysis 
of GTP to GDP (4). 
 
2.2.3.1   Small G-proteins 
Small monomeric G-proteins rely on external guanine nucleotide exchange factors (GEFs) 
for their activation, and GTPase activating proteins (GAPs) for deactivation. An 
instructional example is the human homologues of Harvey or Kirsten Rat Sarcoma virus 
oncogenes, the p21 Ras family of GTP-binding proteins. This family consists of three 
members, Ha-Ras (also known as H-Ras), Ki-Ras (K-Ras) and N-Ras. Ras is activated by 
guanine nucleotide exchange factors carrying the CDC25 homology domain. To date, the 
GEFs mSOS, Ras-GRF1/2 CalDAG-GEFII (RasGRP) and CalDAG-GEFIII (RasGRP3), as 
well as PDZ-GEFs have been found to contain such a domain, and can thus active Ras 
(5,6). CalDAG-GEFI and certain PDZ-GEFs activate the Ras-related proteins Rap1 and 
Rap2 which are also small monomeric G proteins. 
   Ras displays a weak intrinsic GTPase activity that mediates the hydrolysis of bound GTP 
to GDP and thereby inactivation of Ras. However, the inactivation of Ras is enhanced by 
GAPs such as GAP1m, NF-1 and p120 GAP (6). Ras is a major component of the mitogen 
activated protein kinase cascade, involved in growth factor signaling as well as GPCR 
signaling. Constitutively active mutants of Ras can give rise to uncontrolled growth and act 
as potent oncogenes. The role of Ras in MAPK cascades will be discussed more thoroughly 
in chapter 2.3. The exchange factor Ras-GRF1 is presented in detail in chapter 2.3.1.4. 
   Other examples of small monomeric G-proteins in the Ras family of GTP-binding 
proteins are Rho, Rac and Cdc42. They regulate various physiological responses through 
actin cytoskeleton rearrangements (7). 
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2.2.3.2   Large polymeric G-proteins 
Polymeric G-proteins consists of at least one subunit that shows intrinsic GTPase activity, 
which thereby constitutively deactivates the protein by hydrolysing GTP.      
   Heterotrimeric G-proteins are made of three different subunits, α, β and γ, and are 
responsible for conveying the primary signal from the GPCR to an intracellular amplifier. 
The α-subunit is involved in receptor-effector coupling and is bound to the plasma 
membrane by a myristoylated and palmitoylated N-terminus. It exerts GTPase enzymatic 
activity and binds either a molecule of GTP (activated state) or its hydrolysis product GDP 
(inactivated state). The artificial GTP analogue GTPγS cannot be hydrolyzed and may thus 
be used to activate the α-subunits for very long periods under experimental conditions. 
   The β- and γ-subunits are tightly associated and do not separate in vivo. The two subunits 
are commonly referred to as the Gβγ-dimer, and are attached to the plasma membrane by a 
geranylgeranyl group at the C-terminus of the γ-subunit. The Gβγ-subunit can play several 
roles in intracellular signaling, for example, facilitation of receptor phosphorylation and 
desensitization, activation of K+ channels, modulation of Gα-activation, activation of PLA2 
and PLC, activation of PI3K and regulation of calmodulin. It is however, the Gα-subunit 
which is generally thought of as the main effector of signal transmission. The Gα-subunits 
are divided into four major classes, Gαs, Gαi, Gαq, and Gα12 (see tables 2.3 and 2.4), with 
several subtypes adding to the complexity. 
 
 
Table 2.3   The four major classes of the Gα-subunit. 
 Immediate targets Cellular effects 
Gαs Activation of adenylyl 
cyclase (AC) 
AC catalyzes the formation of cAMP from ATP. cAMP 
activates PKA and Epac. 
Gαi Inhibition of AC (as well as 
activation of inwardly 
rectifying potassium 
channels.) 
Inhibition of cAMP formation. 
Gαq Activation of  
phospholipase Cβ (PLCβ) 
PLCβ cleaves membrane phosphotidylinositol-4, 5-
bisphosphate (PIP2) to release two second messengers: 
diacylglycerol (DAG) and inositol-(1, 4, 5)-trisphosphate 
(IP3). IP3 causes release of Ca2+ from intracellular stores, 
which together with DAG activates PKC. Ca2+ is in it self 
a ubiquitous second messenger and can modulate the 
activity of many proteins. 
Gα12 Activation of Rho GEFs Activation of Ras (directly via GEFs) and the Jun N-
terminal kinase signaling module and Na+/H+ exchangers. 
 
 
 
The Gαs-subunit is the target of the cholera toxin (CTx) liberated by Vibrio cholerae. CTx 
catalyzes the transfer of ADP-ribose to Gαs which inhibits its intrinsic GTPase activity and 
thus makes Gαs constitutively active. This causes persistent activation of adenylyl cyclase. 
Associated with the epithelial lining of the intestine, this causes a massive loss of salts and 
water from the cells, a severe diarrhea, the predominant symptom of a V.cholerae infection.  
   The Gαi-subunit on the other hand, is the target of pertussis toxin (PTx) which is 
produced by B.pertussis. PTx ADP-ribosylates Gαi, and this prevents Gαi from interacting 
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with its activated receptor, causing it to be retained in its GDP bound state. Gαi thereby 
sequesters Gβγ-subunits, and fails to inhibit AC with a resulting increase in intracellular 
cAMP. Both CTx and PTx are employed in various ways as experimental tools to 
investigate signal transduction pathways. 
   There is considerable diversity in the G-protein subunit gene family. Cloning and 
sequencing of cDNAs has defined not only the four main classes of α-subunits, but also at 
least 16 isotypes within this gene family. The β- and γ-subunits also exist in several 
isoforms. At least 6 of the former and 12 of the latter have been identified, and some of the 
subunits have splice variants or are differentially modified, contributing to the total 
diversity. Taken together there are more than 1000 theoretically possible combinations of 
heterotrimeric G-proteins, and it is thought that expression of different isotypes within a G-
protein confer a type of subtle long term regulation of signal transduction in a cell, either by 
dampening or sensitization. It is also becoming clear that individual GPCRs on the cell 
surface recognize specific combinations of heterotrimeric G-proteins, which implicates that 
two receptor isotypes binding the same ligand may produce different effects intracellularly 
(8). 
   As described before, the binding of ligand to the receptor results in a conformational 
change in the receptor’s intracellular regions, allowing interaction with specific G- proteins. 
This interaction in turn causes a conformational change in the G-protein which facilitates 
release of GDP and binding of GTP, leading to dissociation of the Gα- and Gβγ-subunits. 
The separated subunits can then bind to and regulate various intracellular effectors. 
 
 
Table 2.4   Various G-protein coupled receptors (GPCRs), their ligands and G-proteins 
Receptor Ligand G-Protein 
β1-AR, β2-AR, β3-AR Catecholamines (NA) Gs 
D1, D5 Dopamine (DA)  
5-HT4(a), 5-HT4(b), 5-HT6,  
5-HT7(a), 5-HT7(b), 5-HT7(d) 
Serotonin (5-HT)  
H2 Histamine  
A2A, A2B Adenosine  
M1, M3, M5 Acetylcholine Gq 
α1A-AR, α1B-AR, α1C-AR, α1D-AR Catcholamines (NA)  
5-HT2A, 5-HT2B, 5-HT2C Serotonin (5-HT)  
H1 Histamine  
ETA, ETB Endothelin  
M2, M4 Acetylcholine Gi/o 
α2A-AR, α2B-AR, α2C-AR Catecholamines (NA)  
D2, D3, D4 Dopamine (DA)  
5-HT1A, 5-HT1B, 5-HT1D,  
5-HT1E, 5-HT1F 
Serotonin (5-HT)  
A1, A3 Adenosine  
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2.2.4   Adenylyl cyclase and cyclic AMP 
 
 
 
 
 
 
 
The Gαs-subunit activates adenylyl cyclase which catalyzes the formation of cAMP from 
ATP. The binding of an extracellular ligand to a Gs-coupled receptor may cause a more 
than 20-fold increase in intracellular levels of cAMP within seconds (9). The rapid 
production of cAMP is accompanied by the equally rapid breakdown to AMP by specific 
phosphodiesterases (PDEs). There are eleven families of PDEs (PDE1 – PDE11) with 
Figure 2.3   Activation and inhibition of adenylyl cylcase by several mechanisms. 
GRK: G-protein coupled receptor kinase, AC: Adenylyl cyclase, CaM: Calmodulin, Epac: Exchange 
factor directly activated by cAMP. RGS: Regulator of G-protein signaling, CREB: cAMP response 
element-binding protein, PDE: Phosphodiesterase. 
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several isotypes within each family. They differ in tissue and cellular distribution as well as 
regulation, and play a major role in controlling the response from cAMP, discussed in 
chapter 2.2.6. 
   There are at least nine different isoforms of adenylyl cyclase (designated AC1 through 
AC9). They differ considerably in regulatory properties and expression levels in various 
tissues. The AC4, AC7 and AC9 isoforms are found in most cells, whereas AC1 and AC8 
are restricted to neuronal tissues and AC5 is found mainly in the heart and brain (10). 
   Adenylyl cyclases are integral membrane proteins that consist of two bundles of six 
transmembrane segments. Two catalytic domains extend as loops into the cytoplasm and 
comprise the enzymatic actions of the protein. 
   Regulation of AC is not a simple matter of turning on and off by Gαs and Gαi, 
respectively. Gβγ-dimers, PKC, PKA, calmodulin dependent kinase II and 
calcium/calmodulin are all implicated in AC regulation, either by activation or inhibition 
(11). Ultrastructural labelling has demonstrated a close spatial association of ACs with sites 
of calcium entry in many cell types. It thus appears that there is tight integration between 
cAMP and calcium, the cell's two major second massagers (12). The specific consequences 
of these cooperative networks with accompanying complex regulatory mechanisms remain 
to be elucidated. Integration of inputs from several signaling pathways seems to play a 
crucial role in cellular control (13). 
   Elevation of cAMP is primarily associated with the activation of Protein Kinase A, but 
cAMP is also known to activate Epac and some ion channels (14).  
   The classic effect of cAMP mediated activation of PKA is common to all cells in which 
AC is present, but the final cellular outcomes vary considerably between different tissues 
and depend on proteins further down in the cascade, as summarized in table 2.5. This is true 
for all the G-protein signaling cascades, and in such a perspective, the GPCRs serve as 
general templates for the delivery of signals to cells. 
  
 
 
Table 2.5   Some physiological effects of elevated intracellular cAMP 
Ligand Tissue Effect 
Adrenaline/Noradrenaline Muscle Glycogen breakdown 
Adrenaline/Noradrenaline Heart muscle Increased inotropy and chronotropy 
Adrenocorticotrophic 
hormone (ACTH) 
Adrenal cortex Cortisol secretion 
TSH Thyroid gland Thyroid hormone synthesis and secretion 
Glucagon Liver Glycogen breakdown 
Adrenaline, ACTH, 
glucagon, TSH 
Adipose tissue Triglyceride breakdown 
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2.2.5   Protein Kinase A 
The cAMP dependent serine/threonine kinase, PKA, is the main target of cAMP and has 
been implicated in regulation of a wide range of cellular processes, including transcription, 
metabolism, cell cycle progression and apoptosis. 
   Inactive PKA is a complex consisting of two regulatory (R-) subunits and two catalytic 
(C-) subunits, R2C2. Each R-unit must bind two molecules of cAMP (thus a total of four for 
the whole PKA complex) before activation can come to pass. The C-units are then released 
from the protein complex, thereby exposing their catalytic kinase domains. There is an 
excess of R subunits in the cytoplasm, and therefore when cAMP levels drop, the catalytic 
subunits are rapidly inactivated by the binding of R-subunits and reassembly of the protein 
complex. 
   There are two forms of regulatory subunits present in eukaryotic cells, RI and RII, and 
each exists in two isoforms. PKA is classified as type I or type II depending on the 
associated R subunit. The former is predominantly found in the cytosol whereas the latter 
associates with cellular structures and organelles. Cellular localization is proving to be of 
considerable significance for PKA. Type II PKA is not a free floating enzyme, but is 
anchored to precise locations by so-called A Kinase Anchoring Proteins (AKAPs). Type I 
AKAPs have also been characterized, and the distinct localization of different PKAs keeps 
them in range of specific targets and prevents random and indiscriminate phosphorylation 
(15). 
   The catalytic subunits of PKA function independently and exist in three isoforms (16). 
Each C-subunit consists of two domains, a small domain with several β sheet structures and 
a larger domain containing several α helices (17). The binding sites for the substrate and 
ATP are located in the catalytic cleft between the domains, and when ATP and the substrate 
bind, the two lobes rotate so that the terminal phosphate group of the ATP and the target 
amino acid of the substrate move into the correct positions for the catalytic reaction to take 
place, which is the transfer of one phosphate group from ATP to a serine or threonine 
residue on a protein (17). 
   One target of phosphorylation by PKA is the cAMP Response Element Binding Protein 
(CREB) found in the nucleus of most eukaryotic cells. Phosphorylated CREB (pCREB) 
increases activation of transcription, and pCREB is sometimes used as an indicator of PKA 
activity. This, however, can produce false positive results since CREB is promiscuously 
phosphorylated, for example by ERK1/2 (18). 
   PKA phosphorylation may entail inactivation as well as activation. Examples of the 
former kind are: myosin light chain kinase and Raf-1 (19), whereas examples of the latter 
are Src (20), Rap1 (21) and Ras-GRF1 (22). 
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2.2.6   Regulation of GPCR effector cascades 
For signal transduction to be effective it must be under tight regulatory control. Turning off 
a signal is equally important as turning it on, and there are many systems in place to 
regulate the signals from GPCRs. Feedback inhibition is a common cellular strategy, and is 
often executed by the key protein in a signaling cascade. This ensures that deactivation 
follows promptly after activation, in fact, they are often two sides of the same effector 
system. 
   For example: Signaling through Gs-coupled receptors may be inhibited by direct 
phosphorylation and inhibition of the receptor mediated by PKA (see chapter 2.2.6.1). PKA 
may also phosphorylate some adenylyl cyclase isoforms and thereby inhibit the formation 
of cAMP. Finally, certain phosphodiesterases are phosphorylated by PKA and this 
increases their effect, causing an increased breakdown of cAMP. Taken together, PKA 
helps diminish the sources from which its own activation originates, and thereby shuts the 
signal off. In this respect, PKA may be equally important as a propagator of an intracellular 
signal, as it is for terminating the very same signal. 
   The hydrolysis of GTP from G proteins is facilitated by the presence of specific 
modulators called RGS proteins (Regulator of G protein Signaling). They act as α-subunit-
specific GTPase activators and thus inactivate G proteins. A total of 25 RGS proteins are 
encoded by the human genome, and they all interact with a particular set of G proteins to 
shut off their responses. AGS (Activators of G protein signaling) on the other hand, can 
activate G protein in the absence of GPCRs (23). 
 
 
2.2.6.1   Heterologous and homologous GPCR desensitization 
Agonist independent phosphorylation of GPCRs is termed heterologous receptor 
desensitization, as opposed to homologous desensitization which only affects receptors 
activated by agonists.  
   Inactivation of the G protein-coupled receptors is accomplished by several mechanisms, 
and one proceeds through PKA or PKC. These kinases are key proteins in their respective 
signaling cascades (i.e. the Gs and Gq initiated cascades) and they have the ability to 
phosphorylate GPCRs. This inhibits the ability of the receptor to associate with G-proteins, 
and disrupts the signaling cascade. Both agonist activated receptors and receptors that have 
not been exposed to agonist may be inhibited in this fashion. A consequence of the latter is 
that activation of PKA from one Gs-coupled receptor may inhibit a variety of other GPCRs 
(i.e. heterologous desensitization).  
   Another mechanism for PKA mediated desensitization has been proposed recently. In the 
case of the β2-AR, phosphorylation of the receptor has been suggested to switch coupling 
from Gs to Gi (24). This has also been implicated in activation of growth promoting 
pathways as described in chapter 2.3.2.3, but the hypothesis of G-protein switching is 
controversial and is not generally accepted (25). 
   G-protein coupled receptor kinases (GRKs) specifically phosphorylate and desesensitize 
agonist activated GPCRs and are thus obligate mediators of homologous desensitization. 
Seven distinct isoforms of GRKs exist: GRK1 through GRK7. GRKs are cytosolic proteins 
which are recruited to the plasma membrane in response to GPCR activation. The β-AR 
kinases (βARK1 (GRK2) and βARK2 (GRK3)) are targeted  to the plasma membrane by 
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the association of the C-terminal domain of the kinase with the βγ-subunit of the activated 
G protein. GRKs phosphorylate residues within the third intracellular loop and carboxyl-
terminal domain of GPCRs. This in itself contributes to inactivation of the receptors, but it 
also increases the receptor’s affinity to arrestins (e.g. β-arrestin) which uncouples the 
receptor sterically from G-proteins, and may target the receptor for endocytosis (see 
below). 
 
2.2.6.2   Endocytosis of GPCRs 
The internalization of agonist-activated receptors serves to reduce the number of cell 
surface receptors that are available for ligand binding. The mechanisms involved in 
targeting GPCRs for internalization are the same as those involved in receptor 
desensitization. GPCR endocytosis usually requires GRK phosphorylation followed by β-
arrestin binding. β-arrestins interact with clathrin, targeting agonist-activated GPCRs to 
clathrin coated pits. These pits invaginate and form vesicular structures that pinch off from 
the cell surface in a dynamin dependent manner. The vesicles then carry their receptor 
cargo to endosomal membrane compartments where several outcomes may follow (26). In 
the case of receptors like the β1-AR and the endothelin A receptor, internalized GPCRs are 
dephosphorylated and recycled back to the plasma membrane surface as fully functional 
receptors. On the other hand, some GPCRs (e.g. the endothelin B receptor, and the β2-AR) 
are usually targeted to lysosomes for degradation (27,28). Recycled receptors can thus 
mediate persistent responses to agonist, whereas degraded receptors only mediate transient 
responses since the availability of receptors diminishes. Endocytosis of GPCRs is not only 
implicated in terminating signaling, but also, paradoxally, in the triggering of completely 
new and rather unconventional signals. For example mitogen activated protein (MAP) 
cascades which are normally linked to growth factor receptors. These concepts and more 
are the subject of the following chapters. 
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2.3   The Mitogen Activated Protein Kinase Cascade 
MAPK families play an important role in complex cellular programs like proliferation, 
differentiation, development, transformation, and apoptosis. At least three MAPK families 
have been characterized: The extracellular signal-regulated kinases (ERK), Jun kinases 
(JNK/SAPK, c-Jun amino-terminal kinase) and p38 MAPK. These signaling networks 
regulate the cell cycle machinery and other cell proliferation related proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4   Many roads lead to Rome. A schematic review of ERK1/2 activation by RTKs and the the 
many proposed mechanisms of ERK1/2 activation by GPCRs. For further details, consult with the 
following chapters. 
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2.3.1   Receptor tyrosine kinases activate the MAPK cascades 
Receptor tyrosine kinases (RTKs) are found in all multicellular eukaryotic organisms, and 
according to classic signal transduction theories, growth inducing signals are conveyed 
primarily by these receptors. The signaling cascade mediating activation of MAPKs via 
RTK is portrayed roughly in the upper left corner of figure 2.4. Other MAPK cascades exist 
apart from the classical Ras/Raf/MEK/ERK pathway. Of particular importance are the JNK 
and the p38 cascades. Both are activated by stress, cytokines and growth factors and they 
regulate proliferation differentiation and apoptosis. 
 
2.3.1.1   The Src kinase family 
The Src family of non-receptor tyrosine kinases plays an important part in the activation of 
MAPK cascades by RTKs, both structurally and functionally. The Src family consists of 
nine members in mammals: Src, Yes, Fgr, Yrk, Fyn, Lyn, Hck, Lck and Blk, with various 
biochemical characteristics and an array of cellular targets for phosphorylation (29).  
   Src kinases contain so-called SH (Src homology) domains, i.e. SH1, SH2, SH3 and SH4. 
Put shortly, the SH1 domain constitutes the catalytic domain of the protein (kinase 
activity), the SH2 domain binds to phosphorylated tyrosine residues, the SH3 domain binds 
to proline rich regions and the SH4 domain is important for membrane localization. 
   In addition to their SH2 and SH3 domains, Src kinases also contain the proline rich 
regions to which SH3 domains bind (SH3 domain binding motif) as well as a SH2 domain 
binding motif (a phosphorylated tyrosine residue) on its C-terminal tail. Thus, Src can bind 
to itself, and consequently downregulate its own activity by forming a closed, inactive 
conformation (30). The loss of these bindings as a result of mutations can lead to a 
constitutively active Src molecule and increased growth. Such mutants of Src act as 
oncogenes. The viral cancer-causing counterpart of Src from the Rous sarcoma virus (v-
Src) exists only in the active conformation. 
   Src phosphorylates and activates Raf-1 and Shc, promoting ERK1/2 activation (20) (see 
chapter 2.3.1.2). Furthermore, Src phosphorylates p120-GAP and thereby inhibits its Ras-
GAP activity, thus also promoting ERK1/2 activation (31). Src itself can be activated by 
PKA phosphorylation and inactivated by Csk phosphorylation on distinct sites. 
 
2.3.1.2   The RTK/mSOS/Ras/Raf/MEK/ERK cascade 
When RTKs are activated, various SH2 domain containing adaptor proteins can bind to the 
receptor’s intracellular autophosphorylated tyrosine residues. Examples are, apart from the 
Src kinases, PLCγ, Shc, Crk, Gab-1 and Grb2.  
   Shc serves as an adaptor for SH2 domain containing proteins as it also has an SH2 
domain binding motif. Grb2 may thus bind directly to the receptor, or to a phosphorylated 
Shc. Many proteins contain both SH3 and SH2 domains. Crk is one example, and may bind 
to phosphorylated RTKs through its SH2 domain and to C3G (a Rap GEF) through its SH3 
domain. Another example is Src, which may bind both to RTKs and to the p85 subunit of 
PI3K, a protein which has proliferative and antiapoptotic effects through many 
mechanisms, the most important being activation of Akt kinase (PKB). PI3K may also bind 
to activated RTKs through the adaptor protein Gab-1. A third example is Grb2, to which 
the Ras GEF mSOS may bind.  
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   When bound to Grb2, mSOS is in a position to activate the membrane anchored small 
monomeric G-protein Ras. Activated Ras may bind to the N-terminal Ras binding domain 
of Raf-1 (RafRBD), thereby targeting the latter protein to the plasma membrane. The Raf-
family comprises three members in mammals: A-Raf, Raf-1 (c-Raf) and B-Raf. The 
activity of Raf-1 is regulated through a complex set of mechanisms involving protein-
protein interactions, phosphorylation and dephosphorylation on multiple residues.  
Raf-1 is functionally inhibited when bound to the protein dimer 14-3-3, and PKA 
phosphorylation on Raf-1 potentiates this binding (19). Src phosphorylation on the other 
hand, relieves intrinsic autoinhibition of Raf-1 (20).  
   When Raf-1 binds to Ras, the inhibitory 14-3-3 protein is prevented from binding, and as 
a result, Raf-1 becomes activated. Raf-1 is in turn a protein kinase (known as a MAP kinase 
kinase kinase, MKKK) which mediates phosphorylation and activation of the MAP kinase 
kinases MEK1 and MEK2 (MAP & ERK Kinases) on the serine residues 218 and 222. 
Finally, MEK1 and MEK2 dually phosphorylate and activate ERK1 and ERK2 
(Extracellular Signal-Regulated Kinases, or MAP kinases p44 and p42) and this completes 
the sequence. 
 
2.3.1.3   Extracellular signal-regulated kinases 
Five subtypes of these MAP kinases exist, designated ERK1 – ERK5, ERK 1 and ERK2 
(ERK1/2) are the best studied. Dual phosphorylation on Thr202 and Tyr204 on ERK1 and 
Thr183 and Tyr185 on ERK2 by MEKs is necessary for the full activation of these MAP 
kinases. Activated ERK1/2 have targets in the cytosol, but also translocate into the nucleus 
and activate transcription factors, changing gene expression to promote growth, 
differentiation or mitosis. ERK1/2 play a pivotal role in the control of cell cycle 
progression. 
 
2.3.1.4   Ras-GRF1 
The Ras specific exchange factor Ras-GRF1 (CDC25Mm) is localized to the plasma 
membrane through an amino-terminal Pleckstrin homology (PH) domain (32). How this 
targeting is accomplished is somewhat unclear, but it may involve binding to either 
membrane phospholipids (e.g. phosphoinositides) or Gβγ subunits. 
   Ras-GRF1 is activated by calcium and the release of Gβγ-subunits from heterotrimeric G 
proteins (33). Ca2+ dependent activation is mediated through binding of calmodulin to an 
IQ motif on Ras-GRF1 (34). Furthermore, PKA mediated phosphorylation on Ser898 in the 
human sequence (which corresponds to Ser916 in the mouse sequence) is required for full 
activation (22). Ras-GRF1 is also a substrate for CaM Kinase II (35), but the cellular 
significance of this is unknown. 
   Ras-GRF1 has also been shown to exhibit Rac GEF activity, mediated by Src 
phosphorylation, but this phosphorylation does not influence Ras GEF activity (36). Rac is 
known to activate the JNK cascade. On the other hand, Lck, another member of the Src 
family kinases, is able to stimulate the GEF activity of Ras-GRF1 on H-Ras, thus 
promoting activation of ERK1/2 (31).  
   Ras-GRF1 has been reported to be found mainly in brain neurons (37), and it is highly 
expressed in the rat brain compared with the mSOS (22). It is thus thought to play a 
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significant role in Ras activation in the CNS. Ras-GRF1 has also been found in the lung 
and pancreas, and several tumor cell lines (38,39). However, its full role in ERK1/2 
activation resulting from GPCR signaling is yet to be determined. 
 
2.3.2   Activation of ERK1/2 by GPCRs 
Since the discovery that GPCR signaling cascades can activate the pathways originally 
thought of as exclusive for RTKs, the prospects of crosstalk and transactivation has been a 
field of intense research. Current data suggests that there is no single dominant pathway for 
ERK1/2 activation via GPCRs, not even from a single class of GPCRs. It seems that several 
pathways work in cooperation or opposition, and produce a mutable system which is 
dependent on the specific complement of GPCRs present and the available machinery in 
the particular cell. Transactivation of RTKs, or crosstalk with the typical MAPK proteins, 
seem to be important, but exactly how this is accomplished is still shrouded with 
uncertainty. This uncertainty has arisen because mechanisms operating in a particular cell 
type for specific GPCRs may not operate correspondingly in another model system (40). 
For a brief summary of current theories, confer with figure 2.4. It seems there are as many 
mechanisms as there are scientists exploring them. The following chapters consider more 
thoroughly how different classes of GPCRs may activate ERK1/2. 
 
2.3.2.1   Activation of ERK1/2 through Gq-coupled receptors 
Gq-coupled receptors activate ERK1/2 in a process involving PLC, IP3, Ca2+ and PKC. 
PKC can phosphorylate and activate Raf-1 directly, which in itself is sufficient to activate 
ERK1/2. 
   In addition, Ca2+ can activate several CaM dependent kinases, which may phosphorylate 
Pyk2 (proline-rich tyrosine kinase 2). Phosphorylated Pyk2 acts as a docking site which can 
bind and activate the cytoplasmic kinase Src (41) which subsequently may induce 
activation of Raf-1 and Shc. Shc binding to Src can recruit Grb2 to Pyk2 with the resulting 
activation of the ERK1/2 cascade through mSOS and Ras with further activation of Raf-1.    
   The increased intracellular levels of Ca2+ may also activate calcium dependent GEFs 
specific for Ras as described in chapter 2.2.3.1. This may also contribute to the final 
activation of ERK1/2 mediated by Gq-coupled receptors.   
 
2.3.2.2   Activation of ERK1/2 through Gi-coupled receptors 
Gi-coupled receptors are proposed to activate ERK1/2 through the Gβγ-subunit. The use of 
PTx which effectively inactivates Gαi and sequesters Gβγ-subunits (as discussed under 
chapter (2.2.3.2), has shown that the Gβγ-subunit is necessary for the activation of ERK1/2 
(42). Consistent with this, overexpression of Gβγ-subunits is sufficient to activate ERK1/2 
through a mechanism dependent on PI3K, Src and Shc as outlined in figure 2.4 (43). 
   In addition, PTx sensitive Gαi subunits have been shown to activate ERK1/2 in a manner 
independent on Gβγ, Ras and PI3K (44), but additional mechanistic details of this pathway 
are diffuse. 
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Figure 2.5   The chemical 
structure of serotonin 
2.3.2.3   Activation of ERK1/2 through Gs-coupled receptors 
Elevated cAMP levels can increase, decrease, or not influence the activation state of 
ERK1/2 in a cell type dependent manner.  PKA phosphorylates and thereby inhibits Raf-1 
(45), which is thought to be the main inhibitory mechanism of PKA on ERK1/2 activation.  
   In a number of cases, Rap1 has been implicated in the activation of ERK1/2 (21). Rap1 is 
activated by PKA or the cAMP-dependent GEF Epac which is specific for Rap1. Activated 
Rap1 is thought to induce activation of ERK1/2 through B-Raf and MEK (21).  
   In some cell types, however, B-Raf is not expressed at detectable levels, or is expressed 
but seemingly does not play a significant role in ERK1/2 activation. It has been proposed 
that the cytosolic kinases of the Src family are involved instead (46). Src may be activated 
via PKA phosphorylation or by direct interaction with β-arresin. This last case may indicate 
that activation of ERK1/2 could be linked to GPCR desensitization (47). In either case, 
activated Src can stimulate the recruitment of mSOS to RTKs or Pyk2 as described earlier, 
with subsequent activation of ERK1/2. 
   For the β2-adrenoreceptor (β2-AR) it has been published that PKA dependent 
phosphorylation of the receptor may cause it to switch coupling from Gs to Gi (24). This is 
thought to mediate not only desensitization, but also activation of ERK1/2 through a 
cascade involving β-arrestin, Src and dynamin. β-arrestin-bound β2-AR is believed to form 
a complex with the EGF receptor, internalize with it and transactivate it (48). The 
hypothesis of G protein switching is, however, still a matter of controversy (25). 
   The Gs-coupled serotonin receptors 5-HT4(b) and 5-HT7(a) have been shown to activate 
ERK1/2 in a manner dependent on Ras and partly dependent on PKA, but independent of 
Rap1, but the link between PKA and Ras is yet to be elucidated (49). 
 
 
2.4   Serotonin and its Receptors 
Serotonin (fig. 2.5) was first discovered in the 1930’s 
when Vittorio Erspamer was searching for substances 
capable of causing smooth muscle contraction. He 
named this substance enteramine, and it was later 
coined serotonin when in the late 1940’s Irving Page 
isolated this vasoconstricting substance from serum. Its 
structure was reported in 1949, and in 1953, Betty 
Twarog discovered that serotonin was also operating as 
a neurotransmitter in the human brain. 
 
2.4.1   Serotonin (5-hydroxytryptamine, 5-HT) 
Serotonin is a vasoactive biogenic amine which functions as hormone and a 
neurotransmitter with many effects throughout the human body. Serotonin is made from its 
precursor, the amino acid L-tryptophan by hydroxylation of the indole ring at C-5 and 
amino acid decarboxylation. Serotonin is either stored in vesicles or rapidly degraded by 
monoamine oxidase (MAO) to 5-hydroxyindoleaceticacid (5-HIAA). 
   About 90% of all serotonin in the body is found in enterochromaffine cells in the 
gastrointestinal mucosa, mainly in the duodenum. These cells produce and store serotonin 
 23
themselves, and are the main source of circulating serotonin. Basal enteric release of 
serotonin is augmented by mechanical stress such as stretching of the intestines by the 
passage of food. Such release of serotonin causes contraction of gastrointestinal (GI) 
smooth muscle cells, increases tone and facilitates peristalsis. The effect is mediated 
directly by serotonin receptors on smooth muscle cells and also indirectly through the 
enteric nervous system by stimulating ganglion cells. 
   Another important site of serotonin function is the central nervous system where it acts as 
a neurotransmitter. It is synthesized and stored by serotonergic nerons, of which there are 
about 300.000 in the human brain. Most of these originate from the raphe nuclei, but the 
extensive axonal projection system arising from these neurons bears a tremendous number 
of collateral branches so that the 5-HT system densely innervates nearly all regions of the 
CNS. Serotonin modulates and controls a wide range of behavioral and physiological 
processes including cognition, learning/memory, ingestion, blood pressure, perception of 
pain, nausea/vomiting, thermoregulation, circadian rhythms, aggression, depression and 
anxiety. Peripheral seretonergic neurons are found in many tissues and organs including the 
heart, kidneys, lungs, spleen urinary bladder and blood vessels in addition to the 
gastrointestinal tract. 
   In the cardiovascular system blood platelets are the major source of circulating serotonin. 
Blood platelets have no ability to synthesize serotonin themselves, but they use active 
transport mechanisms similar to that of serotonergic nerve endings to gather serotonin 
released from the enteric nervous system. Blood platelets can store this serotonin in 
granules and release it upon activation. Such activation is mediated by platelet contact and 
adhesion to subendothelial collagen via glycoprotein receptors interacting with fibrinogen, 
vonWillebrand factor, fibronectin and vitronectin. This leads to the classical thrombus 
formation and the release of many chemical mediators, among them serotonin. The effects 
of serotonin depend on the localization from which it is released. In the vascular system, 
serotonin can cause both vasodilation (mainly in arterioles and large veins), and 
vasoconstriction (mainly in large arteries and precapillary vessels), but many exceptions 
exist depending on exact vessel site (50). In the heart, serotonin mediates both 
cardioexcitation (increased inotropy and chronotropy) through a direct action (51), and 
cardiodepression indirectly via stimulation of the central nervous system, probably 
mediated through excitation of sensory afferent vagal nerves (51). 
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2.4.2   Classification of serotonin receptors 
There are at least 14 subtypes of serotonin receptors. All of them are GPCRs, except the 5-
HT3 receptor which is an ion channel (52). Based on structural, functional and 
pharmacological criteria, the serotonin receptors are grouped into seven families (table 2.6). 
 
 
Table 2.6   Overview of the human 5-HT receptor families 
Family Members Isoforms* Coupling Intracellular effect 
5-HT1 1A, 1B, 1D, 1E, 1F Not known Gαi/o Inhibition of AC 
5-HT2 2A, 2B, 2C Yes Gαq/11 Activation of PLC 
5-HT3 3A+3B (heteromeric), 3C Yes Na+/K+/Ca2+ Depolarization 
5-HT4  4(a) - 4(h) Gαs Stimulation of AC 
5-HT5 5A, (5B) Not known Unknown Inhibition of AC? 
5-HT6  Not known Gαs Stimulation of AC 
5-HT7  7(a)  
7(b)  
7(d) 
Gαs Stimulation of AC 
* produced by alternative splicing or mRNA editing. 
 
 
Whereas most of the 5-HT receptors are encoded by a single exon and do not contain splice 
variants, the 5-HT4 and 5-HT7 receptors do (53). In addition, the 5-HT2C receptor is a target 
for mRNA editing, producing several functional isoforms (54). 
   To discuss the enormous variety in function, localization and physiological effects of the 
serotonin receptors is beyond the scope of this thesis. In summary, the 5-HT1 receptors are 
found mainly in the CNS, the 5-HT2 receptors are found mainly in the CNS, 
skeletal/smooth muscle and kidneys, the 5-HT4 receptors are found in the CNS, GI tract, 
vascular smooth muscle, urinary bladder and heart, and the 5-HT6 receptor is found in the 
brain only. A more comprehensive outline of the 5-HT7 receptors is the subject of chapter 
2.4.4. 
 
2.4.4   The human 5-HT7 receptors 
There are three human 5-HT7 receptor splice variants, 5-HT7(a), 5-HT7(b) and 5-HT7(d). 
Structurally they differ only in their intracellular C-termini (55,53) (fig. 2.6). The receptors 
share only low sequence homology with the other members of the 5-HT receptor family 
(39% with the Gs-coupled 5-HT6 receptor and 46% with the 5-HT4 receptor), but 
functionally many similarities exist between the various Gs-coupled serotonin receptors. 
   The 5-HT7(b) (432 amino acids) is a truncated version of the 5-HT7(a) receptor (445 aa), 
whereas the 5-HT7(d) receptor (479 aa) is an extended variant with two extra putative 
phosphorylation sites, a PKC and a casein kinase II site respectively. A non-classical group 
II PDZ binding motif is present on the C-terminus of the 5-HT7(b) receptor, but the cellular 
significance of this is unknown (56). The phosphorylation sites and the PDZ motif could 
have important functional consequences, such as different G-protein-coupling efficiency or 
different susceptibility to desensitization. 
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All the 5-HT7 receptors modulate AC positively through Gαs with no detected difference 
between the splice variants (57,58). In fact, the various isoforms have been shown to share 
indistinguishable pharmacological and signal transduction properties, differing only 
somewhat in tissue distribution. Usually however, they are even co-localized in the same 
tissue, though at various relative abundance (58,59).  
   The 5-HT7 receptors are believed to play an important regulatory role in CNS, especially 
in the limbic and cortical systems, as well as in the hippocampus and hypothalamus. 
Circadian rhythm and depression have been linked to 5-HT7 receptor localization and 
function (60). In peripheral tissues, the receptors generally mediate smooth muscle 
Figure 2.6   The human 5-HT7 receptor splice variants. * putative PKC phosphorylation site, 
† putative casein kinase II phosphorylation site (adopted from Vanhoenacker et al. (60)) 
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relaxation, and have been found in blood vessels, including the coronary arteries, the 
descending colon and the ileum. 
   In membranes from HEK293 cells stably or transiently expressing either of the three 
human 5-HT7 receptor splice variants, basal AC activity is elevated higher than in non-
transfected HEK293 cells (61), indicating some form of constitutive activity of the 
receptors. 
 
2.4.4.1   Activation of ERK1/2 through 5-HT7 receptors 
Agonist stimulation of endogenously expressed 5-HT7 receptors in cultured rat 
hippocampal neurons induces activation of ERK1/2 (62). This activation is not sensitive to 
PTx, and is therefore unlikely to involve Gi/o-proteins. 
   Activation of ERK1/2 has also been shown in COS7 and HEK293 cells transiently 
transfected with 5-HT7(a) receptors. This stimulation was dependent on Ras and Raf-1, but 
did not require transactivation of EGF receptors (49). 
   The complete mechanism by which ERK1/2 is activated by the 5-HT7 receptors is yet to 
be elucidated (see also chapter 2.4.4.2) 
 
2.4.4.2   The 5-HT7 receptors and calcium 
There are many kinds of Ca2+ channels in the body, but the variety of functions is beyond 
the scope of this thesis. A brief summary is presented in table 2.7. 
 
 
Table 2.7   Summary of some calcium channels and transporters 
Type Main localisation Main functions 
RyR1 (calcium-induced) Skeletal muscle, cerebellum Ca2+ release from ER/SR 
RyR2 (calcium-induced) Cardiac muscle, brain Ca2+ release from ER/SR 
RyR3 (calcium-induced) Brain, smooth muscle Ca2+ release from ER/SR 
IP3R Most nucleated cells Ca2+ release from ER/SR 
T-Type (low-voltage-activated)  Cardiac SA node, neurons, 
endocrine cells, smooth muscle. 
Pacemaking, repetitive firing 
L-Type (high-voltage-activated) Smooth muscle, skeletal muscle, 
cardiac myocytes, endocrine cells, 
neurons. 
Excitation-contraction coupling, 
hormone release, 
neurotransmitter release 
Na+/Ca2+ exchanger Most nucleated cells, SR/ER, 
plasma membrane 
Removal of cytoplasmic Ca2+ 
Ca2+ ATPase Most nucleated cells, SR/ER, 
plasma membrane 
Removal of cytoplasmic Ca2+ 
 
 
Several mechanisms may be responsible for increase in free intracellular calcium (Ca2+i) in 
HEK293 cells. Release of calcium from the endoplasmatic reticulum through the classical 
ryanodine receptors (RyR) is a possibility (63). The main function of RyRs is to amplify 
Ca2+i signals through calcium-induced calcium release, but may also be stimulated by 
protein phosphorylation mediated by PKA or calmodulin-dependent kinase II (64). 
   The 5-HT7(a) receptor has been shown to activate the neuron specific isoforms of adenylyl 
cyclase, AC1 and AC8 (65). These types of adenylyl cyclase are found in areas of the brain 
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(hippocampus and hypothalamus) where the 5-HT7 receptors have been localized. It has 
been demonstrated previously that activation of the 5-HT7(a) receptor results in increases in 
Ca2+i, which is consistent with an increase in cAMP as a result of activation of the 
Ca2+/CaM sensitive AC1 and AC8 (65). This effect however, was shown to be independent 
of PKC, phosphoinositide turnover and Gi-proteins (65). It could be that direct interaction 
with a Ca2+ channel occurs, possibly mediated by a PDZ domain as suggested for the β2-AR 
(66).  
   In rat glomerulosa cells, activation of endogenous 5-HT7 receptors is associated with an 
increase in AC activity and Ca2+ influx through T-type calcium channels (67). The link 
between the Gs coupled 5-HT7 receptors and Ca2+ is very interesting in the perspective of 
ERK1/2 activation. It has been shown that Ca2+ plays an important role in stimulation of 
ERK1/2 through calmodulin, Src, Pyk2, PKC, Ras-GRF1 and CalDAG-GEFs. It can thus 
be envisioned that activation of the Gs-coupled 5-HT7 receptors leads to an increase in both 
cAMP and Ca2+ with activation of ERK1/2 occurring as a consequence. Exactly how this is 
brought about is currently unknown and needs to be clarified. 
 
 
 
2.5   Background and Purpose of the Present Study 
With basis in the theories presented in the preceding chapters, the main aim of this thesis is 
to elucidate the signal transduction sequences leading from agonist binding to the human 5-
HT7 receptors to activation of ERK1/2. There are two incentives for doing this. First to 
better understand the function of these serotonergic receptor systems at a molecular level, 
as these receptors may play important roles in some pathological conditions. Secondly, and 
most importantly, to discern a possible model system for how Gs-coupled receptors in 
general mediate activation of mitogen activating protein kinases. 
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3   Methods 
3.1   Amplification of DNA plasmids 
When eucaryotic DNA plasmids are transformed into bacteria, they are replicated 
independently of procaryotic chromosomal DNA. Transformation can thereby be used to 
produce high numbers of plasmid construct copies, which in turn can be used in 
transfection procedures of human eucaryotic cells (i.e. HEK293) 
 
3.1.1   pcDNA3.1 vector 
We have used the pcDNA3.1(+) (V1) from Invitrogen extensively and is presented as an 
example of a DNA vector. Other vectors exibit similar qualities.  
   pcDNA3.1(+) is a 5428 bp vector derived from pcDNA3 and designed for high-level 
stable and transient expression in mammalian hosts. The human cytomegalovirus 
immediate-early (CMV) promoter provides high-level expression in most eucaryotic cells, 
including HEK293. In addition, the vector can replicate episomally in cell lines that are 
latently infected with SV40. 
 
3.1.2   Plasmid propagation 
The kit MaxiPrep from QIAGEN was used for amplification of different constructs.  
⋅ pcDNA3.1 with 5-HT7(a) receptor insert 
⋅ pcDNA3.1 with 5-HT7(b) receptor insert 
⋅ pcDNA3.1 with 5-HT7(d) receptor insert 
⋅ pMT2HA with Rap1GAP1 insert 
⋅ pCMV with RasN17 insert 
⋅ pCMV with RasV12 insert 
⋅ pKH3 with HA-Ras-GRF1-wt insert 
⋅ pEGFP-C2 encoding green fluorescence protein (GFP) 
⋅ pcDNA3.1(-) empty vector (V2) 
 
The bacterial cells used for transformation are strains of Escherichia coli. These bacteria 
are pretreated with various chemicals to become competent for DNA transformation. In this 
thesis we used “TOP-10 Chemically Competent E.coli” from Invitrogen, and the 
transformation protocol used was called “TOPO One-Shot”. 
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3.1.3   TOPO One-Shot transformation 
Competent cells are highly sensitive to changes in temperature or mechanical lysis caused 
by pipetting. Transformation should be started immediately following the thawing of the 
cells on ice. Mix by swirling or tapping the tube gently, not by pipetting. 
 
Protocol: 
 
1. Thaw, on ice, one 50 µl vial of One Shot cells for each ligation/transformation.  
2. Add 1 to 10 µg plasmid DNA to 25 µl competent cells and mix gently. 
3. Incubate the cells on ice for 30 min. 
4. Heat shock the cells for exactly 30 s at 42 ºC without shaking. 
5. Transfer the vial immediately to ice and incubate for 2 min without shaking. 
6. Add 250 µl of SOC medium (room temperature). 
7. Cap the tube tightly, shake horizontally at 37 ºC for 1 hour at 225 rpm. 
8. Spread 50 – 100 µl of the transformation mixture on to an LB (Luria Bertani)-
agarose-ampicillin (75 µg ampicillin/ml) plate. 
9. Invert the plate and incubate overnight at 37 ºC. 
 
3.1.4   QIAGEN maxiprep plasmid purification 
The QIAGEN maxiprep plasmid purification kit is used for large-scale plasmid 
preparations. The cells are lysed using a NaOH and SDS containing solution (buffer P2) in 
the presence of RNase A (buffer P1). SDS solubilizes the phospholipid and protein 
components of the cell membrane, leading to lysis and release of cell contents. NaOH 
denatures chromosomal and plasmid DNA, as well as proteins. RNase A is used to digest 
liberated RNA as to minimize RNA contamination. An optimized lysis time will ensure 
that the plasmid DNA is released while the chromosomal DNA remains attached to the cell-
wall. The lysates are neutralized by the addition of acidic potassium acetate (buffer P3). 
The high salt concentration causes potassium dodecyl sulfate (KDS) to precipitate, and the 
denatured proteins, chromosomal cell-wall-bound DNA and cellular debris become 
entrapped in salt-detergent complexes. Plasmid DNA on the other hand, being smaller and 
circular, renatures and remains in solution. Centrifugation removes the unwanted debris and 
the lysates are run through an anion-exchange column consisting of silica beads (100 µm 
particle size) with high density of diethylaminoethyl (DEAE) groups. DEAE is positively 
charged in an acidic environment and will interact with charged molecules, such as the 
phosphate groups on DNA. Degraded RNA, cellular proteins and other debris are not 
retained and appear in the flow-through fraction. Washing with a medium-salt buffer 
(buffer QC) will remove contaminants such as traces of RNA and proteins. Plasmid DNA is 
eluted using a high-salt buffer (buffer QF). The eluted plasmid DNA is desalted and 
concentrated by isopropanol precipitation.  
 
All the buffers mentioned are part of the QIAGEN plasmid kit (see chapter 7.2.1.1) 
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Protocol: 
 
1. Pick one colony from a LB-agarose plate described in 3.1.3 and resuspend it in 5 ml 
LB medium with 75 µg/ml ampicillin. Incubate the culture for 8 h at 37 ºC in a 
shaking incubator (300 rpm). 
2. Transfer the starter culture into 500 ml LB medium with 75 µg/ml ampicillin. Grow 
at 37 ºC over night in a shaking incubator (300 rpm) 
3. Transfer the overnight culture to a centrifuge tube and harvest the bacterial cells by 
centrifugation at 6000 x g (6000 rpm in a Beckman JA-10 rotor) for 15 min at 4 ºC. 
Pour the supernatant off until all medium has been drained. 
4. Resuspend the pellet in 10 ml buffer P1 (containing RNase A) by vortexing and 
pipetting. 
5. Add 10 ml of buffer P2, mix gently but thoroughly by inverting the tube 5-6 times 
and incubate at room temperature for exactly 5 min. (Do not vortex as this can result 
in shearing of the genomic DNA). 
6. Add 10 ml of prechilled buffer P3, mix immediately but gently by inverting 4-6 
times, and incubate on ice for 20 min. A fluffy white material forms and the lysate 
becomes less viscous.  
7. Centrifuge at 20000 x g (12000 rpm in a Beckman JA-17 rotor) for 30 min at 4 ºC. 
Remove the supernatant containing the plasmid DNA promptly. 
8. Recentrifuge the supernatant at 20000 x g (12000 rpm in a Beckman JA-17 rotor) 
for 15 min at 4 ºC. Remove the supernatant containing the plasmid DNA promptly. 
9. Equilibrate a QIAGEN-tip 500 by applying 10 ml buffer QBT and allow the column 
to empty by gravity flow.  
10. Apply the supernatant from step 8 to the QIAGEN-tip and allow it to enter the resin 
by gravity flow.  
11. Wash the QIAGEN-tip with 2 x 30 ml buffer QC.  
12. Elute DNA with 15 ml buffer QF into a centrifuge tube resistant to alcohol. 
13. Precipitate DNA by adding 10.5 ml room-temperature isopropanol to the tube. Mix 
and centrifuge immediately at 15000 x g (10500 rpm in a Beckman JA-17 rotor) for 
30 min at 4 ºC. Carefully decant the supernatant. Mark the tubes prior to 
centrifugation so as to ease the detection of the glassy DNA pellet. 
14. Wash the DNA pellet with 5 ml of room-temperature 70% ethanol, and centrifuge at 
15000 x g for 10 min. Carefully decant the supernatant without disturbing the pellet.  
15. Air-dry the pellet and redissolve the DNA in 500 µl TE buffer. 
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3.1.5   Analysis of DNA Plasmids 
3.1.5.1   Quantification of DNA by UV analysis 
Spectrophotometrical quantification of plasmid DNA is performed by measuring optical 
absorption at λ = 230 nm, 260 nm and 280 nm (OD230, OD260 and OD280).  
   Asp, Glu, Asn, Gln, Arg, and His sidechains have absorption in the region 190 - 230 nm, 
whereas aromatic amino acids (Phe, Tyr and Trp) absorb UV-light around 280 nm. The 
Tryptophane band at 280 nm is clear-cut and specific, and this wavelength is therefore used 
generally to determine protein concentrations. Urea and phenol have absorption maxima at 
230 nm. 
   Nucleotide spectra are complicated to analyze quantitatively because there are many non-
bonded electrons with indistinct transitions giving a multitude of absorptions between 200 
nm and 300 nm. All nucleotides do however have a λmax near 260 nm which is fairly 
specific for the purine and pyrimidine bases. This wavelength can thus be used to estimate 
the nucleic acid concentration in a sample, and combined with the absorption at 230 nm and 
280 nm an approximate purity can be calculated. Contamination by RNA on the other hand 
can not be detected by UV analysis as both RNA and DNA have absorption maxima at 
about 260 nm.  
 
Pure DNA: 
⋅ OD260/OD280 ratio ~ 1.8 - 1.9  
⋅ OD260/OD230 ratio ~ 1.8 - 2.2  
 
DNA absorbs light at 230 and 280 nm also, but to a lesser extent. Absorbance at 230 nm 
indicates contamination by urea, phenol or proteins, whereas absorbance at 280 nm denotes 
mainly protein contamination. A lower value of either ratio (i.e. a relatively lower 
absorbance at 260 nm) indicates contamination. Using OD260 to estimate concentration is 
only valid if the ratios are within their limits, otherwise the solution is not pure nucleic acid 
and the OD260 may include absorbance by other molecules. 
 
 
Given these premises the total amount of DNA can be calculated using the formula: 
 
[DNA] (µg/µl) = OD260 x dilution / 20 
 
Protocol: 
 
1. Tune the spectrophotometer to measure ODs at 230 nm, 260 nm and 280 nm. 
2. Clean the quartz cuvettes with 6 M HCl and then dH2O. 
3. Dilute the plasmid sample 1:100 with a suitable solvent (e.g. TE pH 8.0 or dH20). 1 
ml total volume is sufficient for the cuvette. 
4. Calibrate the apparatus using a blank containing only the solvent and then analyze 
the plasmid at the specified wavelengths. The readout should look like figure 3.1. 
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Sample 230 nm 260 nm 280 nm 260/230 260/280 Conc. 
Ref 0.000 0.000 0.000    
1 0.126 0.270 0.152 2.14 1.78 1.352 
2 0.211 0.426 0.238 2.03 1.79 2.132 
3 0.225 0.480 0.262 2.14 1.83 2.401 
4 0.115 0.250 0.135 2.18 1.85 1.250 
 
 
 
 
 
 
3.1.5.2   Agarose gel analysis 
Agarose gel electrophoresis can be used to distinguish and separate DNA fragments of 
different sizes. Gels with 1.0-1.3% agarose are used for separating small fragments (0.1-2.0 
kilobases), whilst 0.6-1.0% agarose gels are used for separating larger fragments (2.0-10.0 
kb). Due to the negatively charged phosphate groups, DNA molecules will be attracted to 
the cathode in an electrical field. DNA fragments of smaller sizes will migrate faster than 
those of larger sizes because they more readily travel through the polymer meshwork. This 
can thus be used in separating a mixture of fragments according to size. Also, supercoiled 
fragments will migrate faster than linearized fragments and open circles. To determine the 
size of the separated DNA molecules, they are compared to DNA marker fragments of 
known size run on the same gel. The gel is preloaded with ethidium bromide, a substance 
which intercalates between the basepairs of the DNA double helix, and the fragments are 
visualized using UV-light. 
 
Protocol: 
 
0.9% (w/v) agarose gel suitable for 0.5 – 7 Kb DNA. 
1. Dissolve 1.80 g agarose in 200 ml TAE buffer by heating to the boiling point in a 
microwave oven. 
2. Let the solution cool to 50-60 °C and add 20 µl of 2.5 mg/ml ethidium bromide. 
Pour the warm solution carefully into a gel mould fitted with the appropriate comb 
and remove air bubbles by the tip of a pipette. Allow the gel to set at room 
temperature. 
3. Remove the comb, transfer the gel to an electrophoresis chamber and cover it 
completely with 1x TAE buffer. 
4. Prepare the DNA samples with DNA loading buffer. Apply a DNA marker in the 
first lane and samples in the remaining wells. 
5. Run the gel at 50-90 V. 
6. Visualize the DNA in the gel under UV-light. 
 
 
 
Figure 3.1.   Example of a spectrophotometer readout. The image shows an 
example of a readout from the Ultrospec 2100 Pro instrument providing data 
for 230, 260 and 280 nm. Column 3 shows the absorption at 260 nm, and from 
this we can derive the concentration in column 7. Columns 5 and 6 indicate the 
purity of the sample which in this case is acceptable. 
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Figure 3.2   HEK293 cells growing in culture. 
Bright field filter, 20x objective (Olympus 
IX81). 
Samples from the QIAGEN maxiprep plasmid purification protocol described in section 
3.1.4, can be analyzed using agarose gel electrophoresis. Samples from each step in the 
maxiprep protocol must be taken out for this purpose. The samples collected at the 
indicated steps may be analyzed on a 0.9 % (w/v) agarose gel to determine:  
⋅ Whether the growth and lysis conditions were optimal (Lysate supernatants (step 8, 
sample 1)) 
⋅ Whether the efficiency of DNA binding to the QIAGEN resin was satisfactory 
(Flow-throughs (step 10, sample 2)) 
⋅ Whether DNA was lost during the washing procedure (Wash-fractions (step 11, 
sample 3))  
⋅ Contents of DNA in the final eluate (Eluates (step 12, sample 4)) 
 
 
 
3.2   Culturing HEK293 Cells 
HEK293 cells (fig. 3.2) are epithelial 
human embryonic kidney cells 
transformed with adenovirus 5 DNA 
(HAd5) established by F.L.Graham 
in 1977 (68). The cells are 
hypotriploid and form tumours in 
nude mice. The cells grow well both 
in serum-containing and serum-free 
medium, adhere to plastic surfaces 
and have a virtually infinite life 
span. HEK293 cells express several 
receptors that will mediate activation 
of ERK1/2 (e.g. the EGF receptor) 
However, serotonin receptors that 
mediate activation of ERK1/2 are 
not expressed. Therefore, HEK293 
cells were chosen for studying 
activation of ERK1/2 mediated 
through specific serotonin receptors.  
 
 
 
 
 
 
 
 
 
 
 
 34
3.2.1   Thawing cells 
 
Protocol: 
 
1. Remove one vial of cells (1 ml of cell suspension containing ~107 cells) from the 
liquid nitrogen tank. Thaw the suspension in a water bath at 37 ºC until only a tiny 
piece of ice is left. 
2. In a LAF bench, using aseptic procedures, add the cell suspension to a 15 ml tube 
containing 5 ml prewarmed (37 °C) complete medium (DMEM with 10% FCS, 100 
U/ml penicillin and 100 µg/ml streptomycin).  
3. Centrifuge the suspension for 5 min at 160 g. 
4. Resuspend the pellet in 10 ml prewarmed complete medium and transfer to a 100 
mm cell culture plate. 
5. Incubate cells at 37 ºC in a humified atmosphere of 5% CO2 in air over night. 
6. Split cells 1:4 and seed the cells on 100 mm cell culture plates. 
 
 
3.2.2   Splitting cells 
HEK293 cells grow poorly at low confluency (<20%) due to lack of cell contact and 
paracrine growth enhancers. At high densities (>90%) however, the cells tend to aggregate 
and form a very dense monolayer which is difficult to split. Confluent cells at 80-90% (one 
100 mm dish containing approximately 107 cells) form a homogeneous monolayer and are 
readily transfected, thus 1:4 or 1:6 dilution is regarded as optimal when splitting these cells.  
   At 70-80% confluency the HEK293 cells are subjected to a treatment with trypsin-EDTA 
(0.5 mg/ml trypsin and 0.2 mg/ml EDTA in PBS). Trypsin is a proteolytic enzyme and 
combined with the calcium chelator EDTA, the cells are detached from the culture dish 
surface and can be seeded out on new plates. 
 
Protocol: 
 
1. In a LAF bench, using aseptic procedures, remove medium and wash once with 10 
ml sterile 0.9% NaCl solution. 
2. Add trypsin-EDTA to barely cover the cells (approximately 1.5 ml for a 100 mm 
culture dish), and incubate the dish at 37 ºC until the cells detach (1-2 min 
depending on cell confluency). A firm knock on the side of the plate once or twice 
will promote the detachment. 
3. Add 4.5 ml preheated (37 ºC ) complete medium to the plates to inhibit further 
effect of the trypsin-EDTA solution, and disperse the cells by pipetting. Transfer the 
cell solution to a 15 ml tube. 
4. Centrifuge the cell suspension at 160 g for 5 min at room temperature. 
5. Resuspend the cell pellet in 6 ml preheated (37 ºC) complete medium. 
6. Seed the cells out on new plates at a ratio of 1:4 or 1:6 depending on the original 
confluency (about 2 million cells per plate). 
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3.2.3 Freezing cells 
When ordinary cells freeze, their plasmamembranes disrupt and vital parts are damaged 
because of ice crystal formation. Cryoprotective Medium contains 15% DMSO, which 
penetrates the cells and prevents plasmamembrane rupture. A slow freezing process further 
augments survival of the cells. The ideal decrease in temperature for freezing cells is about 
1 ºC per hour, but the process can’t be too slow due to the toxicity of DMSO present in the 
cryo-medium. 
 
Protocol: 
 
1. When the cells are 60-70% confluent, remove the medium, wash the cells with 0.9%  
NaCl and treat the cells with trypsin-EDTA as previously described. 
2. Suspend cells in 10 ml of complete medium. 
3. Centrifuge the cells at 160 g for 5 min at room temperature. 
4. Resuspend the cells in 0.5 ml complete medium (without antibiotics), put on ice and 
add 0.5 ml ice-cold Cryoprotective Medium containing 15% DMSO. 
5. Transfer the cell suspension to a cryotube kept on ice. 
6. Place the cryotube in a styrofoam box at –70 °C, to let the temperature slowly 
decrease over night. Transfer the frozen cells to liquid nitrogen for long term 
storage. 
 
3.3   Cell Experiments 
3.3.1   Transfecting cells 
Transfection is a method used for introduction of exogenous DNA into eucaryotic cells. 
There are several techniques by which this can be accomplished, but for HEK293 cells the 
method employing Lipofectamine (Invitrogen) is widely used and works well, giving 
transfection rates of up to 60%.  Lipofectamine is a 3:1 (w/w) liposome formulation of the 
polycationic lipid DOSPA and the neutral lipid DOPE in water. The plasmid DNAs form 
complexes with the Lipofectamine reagent, these complexes are then able to cross the 
plasma membrane of the cells, and the plasmids can then be replicated and transcribed 
episomally. 
 
Protocol (transient transfection) 
 
1. On 35 mm tissue culture plates, seed 2x105 cells in 2 ml DMEM with 10% FBS per 
plate, and incubate the cells at 37 ºC in a humidified atmosphere of 5% CO2 in air, 
until the cells are 70-80% confluent (This will usually take 18- 24 h). 
2. For each 35 mm dish of cells  prepare the following solutions in sterile tubes:  
Solution A: Dilute 1 µg of DNA into 100 µl serum-free DMEM.  
Solution B: Dilute 9 µl of Lipofectamine reagent into 100 µl serum-free DMEM. 
The amount of Lipofectamine may need to be adjusted depending on cell line 
variations. 
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3. Pour solution B into solution A and mix gently. Incubate at room temperature for 30 
min, then add 0.8 ml serum-free DMEM to the tube containing the DNA-lipid 
complexes. Mix gently. 
4. Wash the cells once with 2 ml serum-free DMEM. 
5. Overlay the transfection solution onto the washed cells. 
6. Incubate the cells for 5 h at 37 ºC in a humidified atmosphere of 5% CO2 in air. 
7. Remove the transfection mixture and add 1.5 ml DMEM with 10% FBS per culture 
plate. 
8. Replace medium 18-24 h after the start of the transfection. 
 
 
3.3.1.1 Analysis of transfection rate 
There are many factors affecting the rate of transfection, the most important being: 
 
⋅ Cell number and confluency of the cells (50-80%) 
⋅ Volume of Lipofectamine (2-20 µl) 
⋅ Amount of DNA (0.5-2 µg)  
⋅ Exposure time to transfection mixture (4-6 h) 
 
The transfection rate can be determined empirically by using plasmids containing the gene 
encoding the green fluorescent protein (GFP), and the mentioned parameters may be 
adjusted to optimal values. GFP is a spontaneously fluorescent protein isolated from the 
jellyfish Aequoria victoria. It is comprised of 238 amino acids and forms a β-barrel with a 
fluorophore located on the central helix. Its wild-type absorbance/excitation peak is at 395 
nm with a minor peak at 475 nm. The cells which have been subjected to successful 
transfection will consequently express GFP and the number of transfected cells can be 
visualized using fluorescent light and compared to the total number of cells (fig. 3.3) 
 
 
Figure 3.3   HEK293 cells transiently transfected with DNA plasmids encoding the 
green fluorescent protein. In the left panel: bright field 20x objective and right panel: 
fluorescence by GFP (wide blue filter) 20x objective (Olympus IX81). 
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3.3.2   Stimulating and harvesting 
Transient or stable transfections with plasmids containing genes encoding either the 5-
HT7(b) or the 5-HT7(d) receptor give us the opportunity to stimulate cells with serotonin, and 
thus observe what cellular signaling cascades are involved. A variety of other chemicals 
may be introduced to the cells to inhibit or induce signals, and combined with co-
transfection with plasmids encoding constitutively active or dominant negative mutants of 
certain proteins in the signaling networks of inquiry, we can deduce what molecular 
mechanisms lay behind cellular effects. 
 
Protocol: 
 
1. Using the transiently transfected cells, replace the medium with serum-free DMEM 
18 h prior to stimulation based on the experience that this results in the lowest 
possible basal ERK1/2 activation. 
2. Carefully add the stimulation mixture (see table 3.1) into the medium and tilt the 
plate to make sure that the chemicals are evenly distributed in the medium. 
3. Incubate for the desired period of time at 37 ºC in a humidified atmosphere of 5% 
CO2 in air. 
4. Remove the culture plates after stimulation and harvest the cells as described below. 
 
 
 
Table 3.1   Concentrations of drugs and their vehicles 
Drug Final conc.  Conc. of drug in  
vehicle (stock) 
Vehicle 
5-HT 20 µM 10 mM 10 mM HCl 
H89 20 µM 25 mM DMSO 
EGF 10 nM 5 µM 10 mM acetic acid 
Thapsigargin 1 µM  1 mM DMSO 
BAPTA-AM 40 µM 50 mM DMSO 
Wortmannin 1 µM 1 mM DMSO 
CAI 20 µM 20 mM DMSO 
GdCl3 20 µM 20 mM dH20 
W-7 25 µM 30 mM DMSO 
KN-93 20 µM 25 mM DMSO 
PP2 20 µM 2 mM DMSO 
PP3 20 µM 2 mM DMSO 
8CPT-2Me-cAMP 30 µM 30 mM 10 mM Tris-HCl 
 
 
The cells are harvested under denaturating and lysing conditions using the harvesting 
solution described under Materials. SDS is a strong detergent which disrupts the cell 
membranes and dissolves membrane proteins, ensuring also protein denaturation. Na3VO4 
(sodium orthovanadate) is added as a potent general inhibitor of phosphatases, including 
phosphotyrosine phosphatases. Vanadate thus prevents dephosphorylation of 
phosphorylated proteins. 
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Protocol: 
 
1. Rapidly remove the stimulatory medium  
2. Place the dish immediately on ice and wash once with ice cold PBS. 
3. Remove the PBS, place the dish upside down on paper towels to absorb excess 
fluids and add 200 µl cold harvesting solution onto the plate. 
4. While keeping the plate on ice, scrape the cells from the bottom of the dish using a 
plastic cell scraper. 
5. Transfer the cell lysate to a sterile 1.5 ml tube. 
6. Shear the lysate six times through a 26 gauge needle. 
7. Snap freeze the sheared lysate in liquid nitrogen. 
8. Thaw the cell lysate at room temperature and let it settle on ice for 10 min. 
9. Centrifuge the cell lysate at 11000 g (14400 rpm in the Eppendorf 5402 centrifuge, 
F-45-18-11 Rotor) for 7 min at 4 ºC. 
10. Transfer the supernatant to a new sterile 1.5 ml tube and discard the pellet. 
11. Snap freeze the sample in liquid nitrogen and keep at -70 ºC for long term storage. 
Alternatively, remove 3 x 5 µl of the sample to quantify the protein concentration 
using the BC assay protein quantification kit using BSA as standard. This to reduce 
the number of thawings and thus minimize the likelihood of dephosphorylation and 
degradation of proteins in the sample. 
 
 
 
3.4    Analysis of Experiments 
3.4.1   Protein quantification 
To determine the amount of protein in each sample, BC 
(bicinchoninic acid) Assay: Protein Quantitation Kit from 
Uptima and a Perkin Elmer HTS 7000 Bio Assay Reader was 
used. Proteins reduce Cu2+ in alkaline solutions to Cu+ and 
two molecules of BCA interact with each molecule of Cu+ 
forming a water soluble red complex with an absorption 
maximum of 562 nm (fig. 3.4). Absorbance is proportional to 
the initial protein concentration between 1-20 µg/ml, 
allowing for spectrophotometric quantification of protein in 
aqueous solutions.  
 
 
 
 
 
 
 
 
 
Figure 3.4   Bicinchoninic  
acid interacting with Cu+ 
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Protocol: 
1. Load a flat bottom 96-well microtiterplate with BSA protein standard, control and 
samples according to figure 3.5. 
2. Add 50 parts of BCA reagent A and one part of BCA reagent B to a tray, mix 
thoroughly and load 250 µl of this solution to each well in the microtiterplate. 
3. Tape a sheet of adhesive plastic over the wells, and shake the plate gently for 
approximately 1 minute. Incubate for 30 min at 37 ºC. 
4. Remove the adhesive plastic and let the plate settle to room temperature for a couple 
of min. 
5. Analyse the samples using a plate spectrophotometer at a wavelength of 570 nm. 
6. Ensure that the standard deviation of the standard curve is below 0.995. If not a new 
plate must be set up. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 s1 s1 s1        
B 125 125 s2 s2 s2        
C 250 250           
D 500 500           
E 750 750           
F 1000 1000           
G 1500 1500           
H C C           
 
 
 
 
 
 
 
3.4.2   SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used to 
separate proteins of various sizes in a sample. 
   Sodium dodecyl sulphate (SDS) is a strong anionic detergent which wraps around the 
polypeptide backbone and disrupts the bonds that make up the three dimensional 
conformation of proteins. β-mercaptoethanol is also added to reduce any disulphide bridges 
within the structures. The samples are heat treated at 95ºC for 5 min to facilitate the 
denaturation process. In essence, the denaturated polypeptides become rods covered with 
negatively charged SDS. The negative charge is proportional to the length of the protein, 
and since the length is proportional to the mass for endogenous proteins, electrophoresis 
through a polyacrylamide gel can be utilized to separate them according to size. The 
intrinsic charge of the polypeptides is of marginal importance as the polypeptides are 
completely covered with the negative SDS. The proteins migrate toward the positive pole 
with a rate of migration dependent only on their size. The smallest fragments will travel 
furthest since they are least obstructed by the dense polyacrylamide network in the 
resolving gel. 
Figure 3.5   Loading of microtiterplate for measurement of 
protein by the BCA method. The protein standards (µg/ml) 
are added as doublets with 20 µL in each well, an albumin 
control (C) can be added optionally as a doublet with 5 µL in 
each well and the cell lysates are added as triplets with 5 µL in 
each well. 
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3.4.2.1 Casting of polyacrylamide gels 
The highly cross-linked gel of polyacrylamide serves as the inert matrix through which the 
denatured SDS-covered proteins migrate. The gel is prepared by polymerization from 
monomers, and the density (pore size) of the gel can be adjusted to suit the size of the 
proteins that are going to be separated. A 10% gel is optimal for separating p44 and p42 
MAPK (the ERK1/ERK2 assay). 
 
Protocol: 
 
1. Wash the glass plates (one long and one short) and the spacers with water and 70% 
EtOH, repeat the procedure twice to ensure that the surfaces are clean. 
2. Assemble the gel sandwich in the casting stand. Ensure that the clamp screws are 
tightened and that the plates are adjusted to avoid leakage. 
3. Insert a comb and mark the glass plate about one centimeter below the comb’s 
perimeter. 
4. Mix the ingredients for the resolving gel of appropriate acrylamide concentration 
gently, ensuring no air bubbles form. Pour into the glass plate assembly carefully 
and overlay gel with 1-butanol to ensure a flat surface and to exclude air. Wash off 
1-butanol with water after gel has set (1 hour). 
5. Remove superfluous water with filter paper and insert the comb. Mix the 
ingredients for the stacking gel, and pour on top of the set resolving gel. Remove 
the comb after the stacking gel has polymerized (30 min), assemble the gel 
sandwich into the electrophoresis tank, and fill with Running Buffer. 
3.4.2.2 Separation of proteins by gel electrophoresis  
Protocol: 
 
1. Transfer a predefined amount of protein (usually between 10 and 20 µg) to a sterile 
1.5 ml tube.  
2. Add the correct volume of diluent (Harvesting Solution) to ensure equal volume of 
each sample.  
3. Add 1/4 of the sample volume of 4x Loading Buffer activated with 10% β-
mercaptoethanol and vortex. 
4. Heat the sample at 95 ºC for 5 min, centrifuge at 14400 rpm (11000 g) for 1 minute 
and vortex again. The finished protein loading samples can be frozen in nitrogen 
and stored at -20 ºC for later use, or can be loaded directly onto a polyacrylamide 
gel. 
5. For each gel, prepare a protein marker by adding 7 µg Precision Plus Protein 
Standards, Dual Color to a 1.5 ml tube. Add 3 µl 4x Loading Buffer and 2 µl dH20. 
Vortex the marker and it is ready to be loaded onto the polyacrylamide gel. 
6. Load the protein marker and the samples onto the gel (12 µl per well) 
7. Run the samples through the stacking gel at a constant current of about 15-20 
milliamperes per mini-gel for approximately 30 min. 
8. Run the samples through the resolving gel at a constant current of about 40-45 
milliamperes per gel until optimal separation is achieved. 
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3.4.3   Western blotting 
After electrophoresis of the proteins, the gel is subjected to electroblotting. The proteins 
negatively charged by SDS, can readily be transfered to a PVDF membrane in an electrical 
field.  
 
Protocol: 
 
1. Remove the gel from the glass plates and place it onto a blotting mesh folder 
containing a pad and three pieces of filterpaper (Whatman 3MM) (pretreated by 
soaking in 1x Blotting Buffer). 
2. Place an activated (15 second pretreatment in methanol, then washed with 1x 
Blotting Buffer) PVDF membrane on the gel, ensuring that no air bubbles remain. 
Place three filterpapers on top of the membrane, as before. 
3. Close the mesh folder and place it in the blotting cassette, and place this in the 
blotting container, already filled with 700 ml pre-chilled (4 ºC) 1x Blotting buffer. 
Make sure the membrane is orientated towards the cathode. Add a magnetic stir bar 
and a cartridge of ice to keep the system chilled through the blotting process. 
4. Attach a power source, and perform the electroblotting at 400 mA for at least 45 
min. The membrane can then be subjected to detection by immunofluorescence. If 
immunostaining is to be performed immediately, rinse the membrane in distilled 
water, if staining is to be performed at a later time, place membrane on a paper 
towel and allow the membrane to dry. The membrane can then be activated again by 
placing for 1 minute in pure methanol and then washed in dH20 for 5 min. 
 
 
3.4.4   Immunodetection 
This is a highly specific method for detection of polypeptides on a Western blot membrane. 
A limitation to the method is that it requires specific antibodies, which can bind to the 
protein of interest. In these studies the proteins of main interest have been ERK1/2 
(p44/p42) and their phosphorylated counterparts ppERK1/2 (see table 3.2). The total 
amount of ERK1/2 provides an internal control, and the amount of phosphorylated ERK1/2 
in each sample must be correlated to the amount of non-phosphorylated ERK1/2 in the 
same sample before conclusions can be made.  
   The principle of immunodetection is the use of primary and secondary antibodies. The 
membranes are first subjected to a solution containing primary antibodies which bind 
specifically to the proteins of interest. A secondary antibody solution is then applied which 
binds to the Fc portion of the primary antibody. The secondary antibodies are conjugated 
with the enzyme horseradish peroxidase (HRP) which catalyzes the breakdown of luminol, 
thus emitting light. Our chemiluminescence reagent (Pierce SuperSignal West Dura 
Extended Duration Substrate) was composed of two components, one being luminol with 
enhancing reagent (a phenol derivative), the other being a peroxide solution, which were 
mixed 1:1 before use. 
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Protocol: 
 
1. Incubate the membrane in 5% dried milk solution in PBS containing 0.05% Tween-
20 at room temperature for 1 h, to non-specifically block the membrane.  
2. Place the membrane in 8 ml of the dried milk solution containing the primary 
antibody at proper dilution. Incubate over night at 4 ºC with gentle tilting. 
3. Remove the primary antibody solution and wash the membrane 3x10 min in PBS 
containing 0.05% Tween. 
4. Incubate the membrane for 1 h at room temperature with gentle tilting in a solution 
containing the secondary antibody at proper dilution. 
5. Remove the secondary antibody solution and wash the membrane 3x20 min in PBS 
containing 0.05% Tween. 
6. Rinse the membrane in dH20 to remove Tween-20. 
7. Remove excess water by placing the membrane gently on a paper tissue. 
8. Incubate the membrane for 5 min in 5 ml chemiluminescence reagent containing the 
HRP substrate (Pierce SuperSignal West Dura Extended Duration Substrate), 1:1 
mixture as described above. 
9. Place the membrane between two sheets of transparent paper, and expose for a 
suitable time (see table 3.2) in a darkroom (e.g. the UVP Epi Chemi II Darkroom). 
10. An optical densitometric scanning may be performed of the digital image obtained 
from the developed membrane to get a quantitative result band intensities. 
 
Table 3.2   Antibody concentrations for the ERK1/2 assay   
(all antibodies were diluted in a solution of 5% dried milk in PBS with 0.05% Tween). 
Phosphorylated ERK1/2 Ab-dilution Exposure time 
Primary antibody  
(Anti-ppERK1/2) 
1:2000  
Secondary antibody  
(Anti-Mouse) 
1:2000 4-7 min 
Total ERK1/2 Ab-dilution Exposure time 
Primary antibody  
(Anti-ERK1/2) 
1:10000  
Secondary antibody  
(Anti-Rabbit) 
1:10000 1-3 min 
 
Table 3.3   Antibody concentrations for the Ras-GRF1 assay 
(all antibodies were diluted in a solution of 5% dried milk in PBS with 0.05% Tween). 
pRas-GRF1 Ab-dilution Exposure time 
Primary antibody  
(Anti-pRas-GRF1) 
1:1000  
Secondary antibody  
(Anti-Rabbit) 
1:1000 4-7 min 
Total Ras-GRF1 Ab-dilution Exposure time 
Primary antibody  
(Anti-Ras-GRF1) 
1:2000  
Secondary antibody  
(Anti-Rabbit) 
1:2000 4-7 min 
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3.4.4.1 Stripping of membranes 
Membranes incubated with primary and secondary antibodies should normally be stripped 
before they are subjected to a new set of antibodies. When stripping the membrane, the 
antibody complex will detach together with a small amount of protein, and thus stripping 
can not be performed indefinitely. 
Protocol: 
 
1. Activate dry membranes in pure methanol for 15 s, wash in dH20 for 5 min. 
2. Incubate the membrane in 0.5 M NaOH for 5 min at room temperature. 
3. Wash 2x5 min in dH20. 
4. Reprobe with a new antibody as described in section 3.4.4. 
 
3.5 Direct cytoplasmic calcium measurements 
Fura-2 is a fluorescent calcium chelator and can be used as a probe to measure intracellular 
calcium concentrations. It is provided as a cell permeable AM (acetoxymethyl) ester which 
is hydrolysed by esterases in the cytosol and trapped there. The spectral properties of fura-2 
differ between its free form when Ca2+ concentrations are low (excitation max. 335 nm and 
emission max. 505 nm) and its calcium bound form when Ca2+ concentrations are high 
(excitation max. 362 nm and emission max. 512 nm). Since both fluorophors emitt 
fluorescent light with a wave length of about 510 nm after excitation, changes in calcium 
concentrations can be determined by imaging the cells at both 340 nm when calcium-bound 
fura-2 emitts light, and 380 nm when free fura-2 emitts light. The ratio 340/380 nm is used 
to reflect the proportion of Ca2+ bound to fura-2, and this correlates with the free 
cytoplasmic calcium concentration. 
Protocol: 
 
1. Mount the 1 cm2 circular polyethylene wells with glass bottom and sterilize 
them with UV-light. 
2. Coat the wells using 200 µl of 50 µg/ml acid soluble collagen type VII from rat 
tale (type 1). This is equivalent to 12.7 µg/cm2. The wells are then dried in a 
LAF-bench over night and can be stored at 4 ºC. 
3. Use transfected HEK293 cells from a 50-70% confluent 10 cm plate and collect 
the cells as described in chapter 3.2.2. Count the cells and dilute them with 
UltraCulture (with 10% PS and 10% Glutamine) so that about 75000-100000 
cells are added to each well, a total of 500 µl cell suspension pr. 10 mm well.  
4. Incubate the cells at 37 ºC in a humified atmosphere of 5% CO2 in air until they 
are 50-75 % confluent. 
5. Remove UltraCulture and wash the cells with 500 µl preheated HPPS buffer. 
6. Expose the cells to 500 µl room temperature Fura-2/AM Loading Mixture 
(corresponding to 5 µM Fura-2) for 20 min at room temperature. 
7. Wash the cells once with 400 µl HPPS buffer and add 400 µl HPPS buffer as the 
final volume before stimulation. Locate cells in the microscope and commence 
calcium measurements at once. 100 µl of the desired stimulation mixture is 
added after 30 s of recording the cells. 
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4   Results 
The work on this thesis is based primarily on the original paper by Norum et al. (49)  and is 
part of a ongoing project in Dr. Levy’s group where the human Gs-coupled serotonin 
receptors, 5-HT7(a), 5-HT7(b), 5-HT7(a), 5-HT4(a) and 5-HT4(b) are investigated concurrently.  
   The majority of the results presented here were conducted with the 5-HT7(b) receptor, 
either in transiently or stably transfected HEK293 cells. The KB1 clone of the stably 
transfected HEK293 cells has been used. Unless otherwise stated in the figure legends, the 
cells have been harvested after stimulation, samples have been prepared of the cell lysates 
and these have been separated on SDS-PAGE and electroblotted over to PVDF-membranes 
before incubation with antibodies and subsequent immunoassay for detection of proteins, as 
described in detail under Methods. 
4.1   Activation of ERK1/2 
4.1.1   The 5-HT7(b) and 5-HT7(d) receptors activate ERK1/2 
HEK293 cells do not endogenously express receptors that mediate activation of ERK1/2 
subsequent to treatment with 10 µM 5-HT (data not shown). We have previously shown 
that the human serotonin receptors 5-HT4(b) and 5-HT7(a) mediate activation of ERK1/2 in 
HEK293 cells. We wanted to investigate whether the human serotonin receptors 5-HT7(b) 
and 5-HT7(d) mediate activation of ERK1/2 in a similar fashion. High resolution time 
courses showed that these receptors mediate phosphorylation of ERK1/2 (fig. 4.1, 4.2, 4.3 
and 4.4) with maximal phosphorylation occuring after 4 - 7.5 min of 5-HT stimulation. 
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Figure 4.1   Activation of ERK1/2 through 5-HT7(b) receptors. A, HEK293 cells transiently 
transfected with plasmids encoding 5-HT7(b) receptors were treated with 5-HT (10 µM) for the 
indicated periods of time and assayed for detection of phosphorylated ERK1/2 as described in 
Methods. Proteins were separated on 10% SDS-PAGE and electroblotted over to PVDF-membranes 
before incubation with antibodies. Western blots were probed with phospho-specific ERK1/2 
antibodies (ppERK1/2; top panel) and subsequently probed with anti-ERK1/2 antibodies (ERK1/2; 
bottom panel) to confirm equal loading. B, the same data is presented in a bar diagram based on 
optical densitometric scanning. 
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Figure 4.2   Activation of ERK1/2 through 5-HT7(b) receptors. HEK293 cells 
transiently transfected with plasmids encoding 5-HT7(b) receptors were treated with 
5-HT (10 µM) for the indicated periods of time. The cells were harvested and 
processed, and the data presented as described in fig. 4.1.  
Figure 4.3   Activation of ERK1/2 in HEK293 cells stably expressing 5-
HT7(b) receptors (KB1 cells). KB1 cells were treated with 5-HT (10 µM) for the 
indicated periods of time. The cells were harvested and the samples were 
processed as described in fig. 4.1. 
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4.1.2   The role of Ras in ERK1/2 activation 
Activation of ERK1/2 mediated through 5-HT4(b) and 5-HT7(a) receptors is dependent on 
Ras (49). Dominant negative and constitutively active constructs of Ras, RasN17 and 
RasV12 respectively, were used to elucidate the role of Ras in the activation of ERK1/2 
through 5-HT7(b) and 5-HT7(d) receptors. HEK293 cells were cotransfected with 5-HT7 
receptors and RasN17 or RasV12 and the cells were treated with 5-HT prior to 
measurements of phosphorylated ERK1/2. The presence of RasN17 inhibited the 5-HT 
induced activation of ERK1/2 mediated through 5-HT7(b) (fig. 4.5A) and 5-HT7(d) (fig. 
4.5B) receptors. Only weak or no additional phosphorylation of ERK1/2 was seen when 
cells cotransfected with 5-HT7 receptors and RasV12 or RasN17 were treated with 5-HT. 
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Figure 4.4   Activation of ERK1/2 through 5-HT7(d) receptors. A and B, HEK293 
cells transiently transfected with plasmids encoding 5-HT7(d) receptors were treated with 
5-HT (10 µM) for the indicated periods of time; A, high resolution and B, extended time 
courses. The cells were harvested and processed as described in fig. 4.1. 
Fig. 4.5  Activation of ERK1/2 through 5-HT7(b) and 5-HT7(d) receptors is dependent on 
Ras. A, HEK293 cells were transiently cotransfected with plasmids encoding 5-HT7(b) or B, 
5-HT7(d) receptors and empty pcDNA3.1(-) vector, dominant negative Ras (RasN17) or 
constitutively active Ras (RasV12) as indicated. The cells were treated with 5-HT (10 µM) or 
vehicle for 5 min, and harvested and processed as described in fig. 4.1. Panels A and B each 
show representative blots of two experiments. 
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4.1.3   The role of cAMP in ERK1/2 activation 
The 5-HT7 receptors couple to Gαs which results in elevated intracellular levels of cAMP. 
The plasma membrane permeable cAMP analogue 8-Br-cAMP is able to induce activation 
of ERK1/2 in many cell types, including HEK293 (69). It’s thus liable to assume that the 
observed activation of ERK1/2 in our system is at least in part dependent on cAMP. 
HEK293 cells were cotransfected with plasmids encoding 5-HT7(b) receptors and 
hPDE4D2, a constitutively active human phosphodiesterase, and the phosphorylation of 
ERK1/2 was determined with Western blots. The 5-HT-induced phosphorylation of 
ERK1/2 was severely reduced in the presence of hPDE4D2 (fig. 4.6), suggesting that 
activation of ERK1/2 is dependent on cAMP. 
 
 
 
 
 
 
 
 
 
 
 
4.1.4   The role of PKA in ERK1/2 activation 
Activation of ERK1/2 mediated through the 5-HT4(b) and 5-HT7(a) receptors was partly 
inhibited in the presence of H89, a PKA inhibitor (49). H89 and a construct encoding PKI, 
an inhibitory peptide for PKA, were employed to elucidate the role of PKA in the activation 
of ERK1/2 through 5-HT7(b) receptors. HEK293 cells transiently transfected with 5-HT7(b) 
receptors or stably transfected KB1 cells were subjected to preincubation with H89.  
   The effect of H89 is dubious: It did not interfere with ERK1/2 activation in five 
experiments of which three were conducted with the KB1 cells and two with transiently 
transfected cells (fig. 4.7A). It did however interfere with ERK1/2 activation to various 
degrees in four experiments of which two were conducted with the KB1 cells and two with 
transiently transfected cells (fig. 4.7B) 
   HEK293 cells were cotransfected with 5-HT7(b) receptors and PKI. In two consecutive 
experiments the presence of PKI did not inhibit activation of ERK1/2 (fig. 4.8A), but it 
interfered partially in one experiment (fig. 4.8B). 
 
 
 
Fig. 4.6  Activation of ERK1/2 through 5-HT7(b) receptors is 
dependent on cAMP. HEK293 cells were transiently 
cotransfected with plasmids encoding 5-HT7(b) and the human 
PDE4D2. The cells were treated with 5-HT (10 µM) or vehicle 
for 5 min, and harvested and processed as described in fig. 4.1. 
The figure shows a representative blot of three independent 
experiments. 
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Figure 4.7   Variable effect of the PKA inhibitor H89.  A, KB1 cells or 
B, HEK293 cells transiently transfected with 5-HT7(b) receptors were 
pretreated with the PKA inhibitor H89 (20 µM) for 25 minutes prior to 5 
min treatment with 5-HT (10 µM) or vehicle as indicated. The cells were 
harvested and processed as described in fig. 4.1. Representative blots of 
both results are shown in panels A and B. 
Figure 4.8   Variable effects PKI overexpression. A and B, 
HEK293 cells transiently cotransfected with plasmids encoding 
5-HT7(b) receptors and PKI were treated with 5-HT (10 µM) or 
vehicle for 5 minutes. The cells were harvested and processed 
as described in fig. 4.1. Representative blots of both results are 
shown in panels A and B. 
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4.1.5   The role of Epac and Rap1 in ERK1/2 activation 
The Rap1 specific exchange factor Epac is activated by cAMP and has been proposed to 
have a role in the activation of ERK1/2 via certain Gs-coupled receptors. The proposed 
sequence is: cAMP → Epac/PKA → Rap1 → B-Raf → MEK → ERK.  
   Activation of ERK1/2 mediated through 5-HT4(b) and 5-HT7(a) receptors occurs 
independently of Rap1 (49). The Epac specific membrane permeable cAMP-analogue, 8-
(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8CPT-2Me-
cAMP) and a Rap1 specific GAP (Rap1GAP1) were used to determine the role of Epac and 
Rap1 in the activation of ERK1/2 through the 5-HT7(b) receptors.  
   The presence of 8CPT-2Me-cAMP did not activate ERK1/2 (fig. 4.9) and cotransfection 
with Rap1GAP1 did not interfere with ERK1/2 phosphorylation (fig 4.10), indicating that 
neither Epac nor Rap1 play any major roles in the activation of ERK1/2 through 5-HT7(b) 
receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10   Activation of ERK1/2 through 5-HT7(b) and 5-HT7(d) receptors is 
independent of Rap1. HEK293 cells were transiently cotransfected with plasmids 
encoding 5-HT7(b) or 5-HT7(d) receptors, and Rap1GAP1 as indicated. The cells were 
treated with 5-HT (10 µM) or vehicle for 5 min. The cells were harvested and 
processed as described in fig. 4.1. The figure shows a representative blot of two 
experiments. 
Figure 4.9   Activation of ERK1/2 through 5-HT7(b) receptors is 
independent of Epac. KB1 cells stably expressing 5-HT7(b) receptors were 
treated with 5-HT (10 µM) or 8CPT-2Me-cAMP (30 µM) for 5 min as 
indicated. The cells were harvested and processed as described in fig. 4.1. 
The figure shows a representative blot of three experiments. 
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4.1.6   The role of PI3K in ERK1/2 activation 
Several studies have implicated PI3K in a pathway mediating receptor induced activation of 
ERK1/2 (42,70). Wortmannin is a fungal metabolite that acts as a potent, selective, cell-
permeable and irreversible inhibitor of PI3K. Preincubation with wortmannin did not 
interfere with the phosphorylation of ERK1/2 (fig. 4.11) indicating that ERK1/2 activation 
through 5-HT7(b) receptors occurs independently of PI3K. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.7   The role of Src in ERK1/2 activation 
The Src family kinases have been implicated as important mediators of ERK1/2 activation 
through GPCRs and RTKs (45, 46, 47). The mechanisms for some of the proposed signal 
transduction sequences have been considererd in the Introduction (chapters, 2.3.1.1, 2.3.1.2 
and 2.3.2.3). PP2 is a potent inhibitor of the Src family tyrosine kinases and selectively 
inhibits Lck, Fyn and Hck. The non-functional peptide PP3 was added as a negative control 
for the inhibitor PP2. PP2 interfered strongly with ERK1/2 activation in our system in a 
concentration dependent manner, whereas PP3 had no effect at 20 µM (fig. 4.12A and B). 
   The tyrosine residue 416 in the C-terminal lobe on Src becomes phosphorylated upon 
activation. Treatment with 5-HT did not change the degree of phosphorylation of this 
residue compared to the basal phosphorylation observed in KB1 cells (fig. 4.13) or in 
HEK293 cells transiently transfected with 5-HT7(b) receptors (data not shown). 
 
 
 
 
 
 
 
 
 
 
Figure 4.11   Activation of ERK1/2 is not blocked by a PI3K inhibitor. 
KB1 cells stably expressing 5-HT7(b) receptors were pretreated with 
wortmannin (1 µM) for 25 min prior to treatment with 5-HT (10 µM) or 
vehicle for 5 min. The cells were harvested and processed as described in fig. 
4.1. The figure shows a representative blot of four experiments, two with 
KB1 cells and two with HEK293 cells transiently transfected with 5-HT7(b). 
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Figure 4.12   The Src inhibitor PP2 interferes with the activation of ERK1/2. 
A, KB1 cells stably expressing 5-HT7(b) receptors were pretreated with 20 µM PP3 
for 25 min, or various concentrations of PP2 as indicated for 25 minutes, prior to 
treatment with 5-HT (10 µM) or vehicle for 5 minutes. B, KB1 cells were 
pretreated with PP3 (20 µM) or PP2 (20 µM) as indicated for 25 minutes, prior to 
treatment with 5-HT (10 µM) or vehicle for 5 minutes. The cells in were harvested 
and processed as described in fig. 4.1. Panel B shows a representative blot of three 
experiments, two of which in KB1 cells and one in transiently transfected cells (5-
HT7(b) receptors). 
Figure 4.13   Phosphorylation of Src in KB1 cells. KB1 cells stably expressing 5-
HT7(b) receptors were with 5-HT (10 µM) or vehicle for 5 minutes as indicated. The 
cells were harvested and separated as described in fig. 4.1. The western blot was 
probed with phosphospecific Src family antibodies (pSrc; upper panel) and 
subsequently probed with anti-Src antibodies (total Src; lower panel) to confirm 
equal loading.  
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4.1.8   The role of Ca2+ in ERK1/2 activation 
Thapsigargin is a drug that inhibits the Ca2+-ATPase family of calcium pumps on 
sarcoplasmic or endoplasmic reticulum, thus mediating a slow but enduring elevation of 
cytoplasmic calcium levels (71). An increase in cytoplasmic calcium levels mediated by 
thapsigargin leads to activation of ERK1/2 in many cell systems (72). As shown in figure 
4.14, ERK1/2 is activated in KB1 cells treated with thapsigargin, indicating that increased 
levels of cytoplasmic calcium is sufficient to induce a phosphorylation of ERK1/2 in this 
cell system. 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, the calcium chelator BAPTA-AM was used to evaluate the role of calcium. 
BAPTA-AM is able to cross plasma membranes in its AM (acetoxymethyl) ester form 
only. The AM form is inactive, but BAPTA-AM is activated by the cleavage of AM by 
intracellular esterases. The phosphorylation of ERK1/2 was reduced in the presence of 
BAPTA-AM (fig. 4.15), indicating that intracellular Ca2+ plays a role in the activation of 
ERK1/2 mediated through 5-HT7(b) receptors. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15  The calcium chelator BAPTA-AM interferes with the 
phosphorylation of ERK1/2. KB1 cells stably expressing 5-HT7(b) receptors 
were pretreated with BAPTA-AM (40 µM) for 25 minutes prior to treated with 
5-HT (10 µM) for 5 minutes. The cells were harvested and processed as 
described in fig. 4.1. The figure shows a representative blot of four experiments, 
two in KB1 cells and two in HEK293 cells transiently transfected with 5-HT7(b) 
receptors. 
Figure 4.14   Activation of ERK1/2 is induced by thapsigargin. 
KB1 cells stably expressing 5-HT7(b) receptors were pretreated with 
thapsigargin (1 µM) for 5 min. The cells were harvested and 
processed as described in fig. 4.1. The figure shows a 
representative blot of three similar experiments. 
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The calcium inhibitor CAI, which inhibits receptor mediated and voltage gated calcium 
influx non-specifically (73,74), was used to further assess the role of Ca2+ in the activation 
of ERK1/2 mediated through 5-HT7(b) receptors. The use of CAI in the KB1 cell system 
reduced activation of ERK1/2 substantially (fig. 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gadolinium (element 64) blocks calcium channels in its Gd3+ form. Gd3+ does not readily 
cross plasma membranes due to its strong hydrophilic nature and thus exerts its effects on 
plasma membrane calcium channels mainly.  
   The effects of Gd3+ on the observed 5-HT induced activation of ERK1/2 are not 
consistent. In three experiments, the presence of Gd3+ interfered with ERK1/2 activation 
(fig. 4.17A) but in four experiments there was no such interferance (fig. 4.17B). The actual 
effect of Gd3+ on the observed 5-HT induced activation of ERK1/2 is still not certain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16   Activation of ERK1/2 is blocked by calcium channel 
inhibitor CAI. KB1 cells stably expressing 5-HT7(b) receptors were 
pretreated with CAI (20µM) for 25 minutes prior to treatment with 5-
HT (10 µM) for 5 minutes. The cells were harvested and processed as 
described in fig. 4.1. The figure shows a representative blot of six 
experiments, four of which in KB1 cells and two in HEK293 cells 
transiently transfected with 5-HT7(b) receptors. 
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To investigate the specificity and effect of the calcium channel blockers Gd3+  and CAI 
more thoroughly, experiments with thapsigargin and the blockers were conducted. Gd3+ did 
not inhibit thapsigargin-induced ERK1/2 activation (fig. 4.18), in fact it augmented 
ERK1/2 activation. CAI, which is known to cross plasma membranes, interfered strongly 
with thapsigargin-induced ERK1/2 activation (fig. 4.18), indicating that CAI is able to 
block calcium channels effectively. 
   Experiments were also conducted with EGF and the calcium channel blockers to see if 
they interfered with EGF-induced ERK1/2 activation. Neither Gd3+, nor CAI, inhibited 
EGF-induced ERK1/2 activation significantly (fig. 4.19). In two experiments however, 
EGF-induced ERK1/2 activation was augmented significantly in the presence of Gd3+ (data 
not shown). 
 
Figure 4.17   Variable effects of a plasma membrane calcium channel 
inhibitor. A and B, KB1 cells stably expressing 5-HT7(b) receptors were 
pretreated with GdCl3 (20µM) for 25 minutes prior to treatment with 5-HT (10 
µM) for 5 minutes. The cells were harvested and processed as described in fig. 
4.1. Panel A shows a representative blot of four experiments where there was 
an effect of GdCl3, three performed in KB1 cells and one in HEK293 cells 
transiently transfected with 5-HT7(b) receptors. Panel B shows a representative 
blot of three experiments where there was no effect of GdCl3, two in KB1 cells 
and one in HEK293 cells transiently transfected with 5-HT7(b) receptors. 
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4.1.9   The role of Ras-GRF1 in ERK1/2 activation 
The role of the Ca2+/calmodulin-activated Ras-specific exchange factor Ras-GRF1 (see 
chapter 2.3.1.4 for details) was investigated. The activity of Ras-GRF1 towards Ras is 
enhanced by PKA-dependent phosphorylation of Ser898, which corresponds to the mouse 
Ser916 site. The two sites share identical amino acid sequences, and thus Ser916 antibodies 
for the mouse sequence of Ras-GRF1 can be used to detect the human Ser898 site. Human 
Ras-GRF1 is mainly expressed in neurons of the central nervous system, and to a certain 
extent in the pancreas and lungs.    
   HEK293 cells were cotransfected with plasmids encoding the 5-HT7(b) receptors and 
plasmids encoding HA-tagged Ras-GRF1-wild-type (HA-Ras-GRF1-wt). Overexpression 
of HA-Ras-GRF1-wt resulted in a massive elevation of the basal level of phosphorylation 
of ERK1/2 which was increased further subsequent to 5-HT stimulation (fig. 4.20). 
   We found that Ras-GRF1 is expressed endogenously in HEK293 cells, and that it 
becomes phosphorylated on Ser898 subsequent to 5-HT stimulation in KB1 cells and 
HEK293 cells transiently transfected with 5-HT7(b) receptor (fig. 4.21A). The same is 
Figure 4.19   EGF induced ERK1/2 activation is not inhibited by Gd3+ or 
CAI. HEK293 cells transiently transfected with 5-HT7(b) receptors were 
pretreated with GdCl3 (20 µM) or CAI (20 µM) for 25 minutes prior to treatment 
with EGF (10 nM) for 5 minutes as indicated. The cells were harvested and 
processed as described in fig. 4.1. The figure shows a representative blot of three 
experiments, one in KB1 cells and two in HEK293 cells transiently transfected 
with 5-HT7(b) receptors. 
Figure 4.18   Effects of Gd3+ and CAI on thapsigargin-induced 
phosphorylation of ERK1/2. HEK293 cells transiently transfected with 5-
HT7(b) receptors were pretreated with GdCl3 (20 µM) or CAI (20 µM) for 25 
minutes prior to treatment with thapsigargin (1 µM) for 5 minutes as indicated. 
The cells were harvested and processed as described in fig. 4.1. The figure 
shows a representative blot of two similar experiments. 
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observed in HEK293 cells cotransfected with 5-HT7(b) receptors and HA-Ras-GRF1-wt 
(fig. 4.21B). As can be seen from figure 4.21B, HA-Ras-GRF1-wt is massively 
overexpressed when cotransfected into HEK293 cells. 
 
 
 
 
 
 
 
 
 
(A) 
 
(B) 
 
 
 
 
 
 
 
 
 
 
Figure 4.20   Ras-GRF1-wt activates ERK1/2.  HEK293 cells transiently 
cotransfected with plasmids encoding the 5-HT7(b) receptor and plasmids 
encoding HA-Ras-GRF1-wt, were treated with 5-HT (10 µM) for 5 
minutes as indicated. The cells were harvested and processed as described 
in fig. 4.1. The figure shows a representative blot of three similar 
experiments. 
Figure 4.21   Ras-GRF1 is present in HEK293 cells and becomes phosphorylated on Ser898.
A, HEK293 cells transiently transfected with plasmids encoding the 5-HT7(b) receptor, were 
treated with 5-HT (10 µM) for 5 minutes. B, HEK293 cells were cotransfected with 5-HT7(b) 
receptors and HA-Ras-GRF1-wt and treated with 5-HT (10 µM) for 5 min as indicated. The cells 
were harvested and separated as described in fig. 4.1. The Western blots were probed with Ser916 
phosphospecific Ras-GRF1 antibodies (pRas-GRF1; A and B top panels) and subsequently 
probed with anti-Ras-GRF1 antibodies (total Ras-GRF1; A and B middle and bottom panels) to 
confirm equal loading. The middle panel in B was exposed for 5 minutes, whereas the bottom 
panel was exposed for 20 seconds. Panel A shows a representative blot of nine experiments, four 
in HEK293 cells transiently transfected with 5-HT7(b) receptors, and five in KB1 cells. Panel B
shows a representative blot of two similar experiments. 
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The Ser898 residue is a PKA specific phosphorylation site, and since PKA is dependent on 
cAMP and 5-HT7(b) receptors couple to Gαs, we wanted to investigate whether a reduction 
in cAMP would interfere with the phosphorylation of this site. 
   HEK293 cells were cotransfected with 5-HT7(b) receptors and hPDE4D2 (described in 
chapter 4.1.3). 5-HT-induced phosphorylation of Ser898 was abolished in the presence of 
overexpressed hPDE4D2, which suggests that this phosphorylation is indeed dependent on 
cAMP (fig. 4.22). 
 
 
 
 
 
 
 
 
 
 
 
 
The PKA inhibitor H89 has been used with various results in previous experiments (figure 
4.7A and B), and the effect of this drug as an inhibitor of phosphorylation on the PKA 
specific site Ser898 on Ras-GRF1 is unclear. Interestingly, in the experiments where H89 
has no effect on ERK1/2 activation (fig. 4.7A), there is little effect on Ras-GRF1 
phosphorylation (fig. 4.23A), and vice versa (fig. 4.7B and 4.23B), indicating that PKA is 
indeed necessary for both ERK1/2 activation and Ras-GRF1 phosphorylation, and that the 
variable effects of H89 on ERK1/2 activation could be due to a variable efficiency of H89 
to block PKA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22   Phosphorylation of Ras-GRF1 on Ser898 is 
dependent on cAMP. HEK293 cells transiently cotransfected with 
plasmids encoding the 5-HT7(b) receptor and hPDE4D2 were treated 
with 5-HT (10 µM) for 5 minutes. The cells were harvested and 
processed as described in fig. 4.21B. The figure shows a 
representative blot of three similar experiments. 
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The role of PKA in the phosphorylation of Ser898 on Ras-GRF1 was further evaluated by 
cotransfection of HEK293 cells with 5-HT7(b) receptors and PKI (described in chapter 
4.1.4). As previously experienced, the effectiveness of PKI as an inhibitor of PKA is 
somewhat variable. In fact, the situation is the same as for H89, as described earlier; In the 
experiments where PKI blocked phosphorylation of Ras-GRF1 (fig. 4.24B) it also blocked 
activation of ERK1/2 (fig. 4.8B), and vice versa (fig. 4.23A and 4.8A), again indicating that 
PKA is in fact necessary for both ERK1/2 activation and Ras-GRF1 phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23   H89 interferes with the phosphorylation of Ras-GRF1. 
A and B, HEK293 cells transiently transfected with plasmids encoding 
the 5-HT7(b) receptor were pretreated with H89 (20 µM) for 30 minutes 
and treated with 5-HT (10 µM) for 5 minutes. The samples are the same 
as described in fig. 4.7. The cells were harvested and processed as 
described in fig. 4.21B. Panels A and B each show representative blots of 
two experiments. 
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EGF strongly activates ERK1/2 through a mechanism known to be independent of Ras-
GRF1, To determine the specificity of the observed phosphorylation of Ras-GRF1 induced 
by 5-HT, HEK293 cells transiently transfected with 5-HT7(b) receptors were treated with 
EGF. As shown in figure 4.25, treatment with EGF did not result in phosphorylation of 
Ras-GRF1 on Ser898. 
 
 
 
 
 
 
 
 
Figure 4.24   PKI interferes with the phosphorylation of Ras-GRF1. A and B, 
HEK293 cells transiently cotransfected with plasmids encoding the 5-HT7(b) receptor 
and PKI were treated with 5-HT (10 µM) for 5 minutes. The samples are the same as 
described in fig. 4.8. The cells were harvested and processed as described in figure 
4.21B. Panels A and B each show representative blots of two experiments. 
Figure 4.25   Phosphorylation of Ras-GRF1 is not induced by EGF. 
HEK293 cells transiently cotransfected with plasmids encoding the 5-HT7(b) 
receptor were treated with 5-HT (10 µM) for 5 minutes. The cells were 
harvested and processed as described in fig. 4.21B. The figure shows a 
representative blot of two identical experiments. 
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4.1.10   The role of Calmodulin and CaMKII in ERK1/2 activation 
Calmodulin is a very important effector of calcium signals, and CaMKII is in turn an 
effector of calmodulin. CaMKII has been implicated in the activation of ERK1/2 (75). 
More importantly, Ca2+/calmodulin is the main activator of Ras-GRF1 (34). We therefore 
wanted to assess whether these proteins play a part in ERK1/2 activation mediated through 
5-HT7(b) receptors. However, neither the calmodulin inhibitor W-7 (fig. 4.25A), nor the 
CaMKII inhibitor KN-93 (fig. 4.25B) interfered with ERK1/2 activation in our system. 
 
(A) 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26   Activation of ERK1/2 is not inhibited by a calmodulin blocker 
(A) or a CaMKII blocker (B). A and B, KBI cells stably expressing 5-HT7(b) 
receptors  were pretreated with A, W-7 (25 µM) or B, KN-93 (20 µM) for 25 
minutes prior to 5 min treatment with 5-HT (10 µM) as indicated. The cells were 
harvested and processed as described in fig. 4.1. Panels A and B each show 
representative blots of three experiments, for each of these three experiments, 
one was conducted in HEK293 cells transiently transfected with 5-HT7(b) 
receptors and two in KBI cells. 
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4.2   Direct Cytosolic Calcium Measurements 
Based on the results obtained with the various calcium inhibitors, there were reasons to 
believe that cytosolic calcium levels were elevated subsequent to stimulation of the 5-HT7(b) 
receptors with serotonin, and that the observed ERK1/2 activation could be dependent on 
such an increase. This possibility was further explored by direct cytosolic calcium 
measurements with fura-2, which make it possible to measure variations in cytosolic 
calcium concentrations in real time. Not all cells generate elevations in cytosolic calcium 
after stimulation, and only responders were selected for further studies. In our experiments 
about 60-80% of the KBI cells produced a detectable calcium signal after stimulation with 
serotonin, which is regarded as normal (prof. J.G. Iversen, personal communication). 
 
4.2.1   The 5-HT7(b) receptors mediate elevation of intracellular Ca2+ 
Our data show that there is a rapid but transient elevation of free intracellular Ca2+ levels of 
60-70% over basal after stimulation with serotonin in the KBI cells (fig. 4.27). In single 
cells we observed increases of up to 130% over basal (data not shown). The duration of the 
main peak varied somewhat between experiments, with a rapid but transient elevation 
lasting about 30-40 s as shown in fig. 4.27, and more elongated plateaus lasting for up to 60 
s (data not shown). 
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Figure 4.27   The levels of free cytosolic calcium is elevated in KBI cells 
subsequent to 5-HT stimulation. KBI cells stably expressing 5-HT7(b) receptors
were loaded with fura-2 for 20 min at room temperature, and direct cytosolic 
calcium measurements were carried out as described under Methods. The cells were 
treated with 5-HT (10 µM) 30 seconds after the start of the recordings. The graph is 
composed of the average cytosolic calcium concentrations in 15 single cells in one 
experiment. The figure is a representative graph of 18 similar experiments. 
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4.2.2   Thapsigargin induces elevation of intracellular Ca2+ 
The KBI cells were treated with thapsigargin as a positive control for elevation of free 
intracellular calcium in this cell system. Treatment with thapsigargin induces a slow but 
long-lasting increase in cytosolic calcium levels. The rise in calcium commences about 30 s 
after stimulation, and a peak level of about 50% over basal is seen after 60 s (fig. 4.28). 
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Figure 4.28   The levels of free cytosolic calcium is elevated in KBI cells 
subsequent treatment with thapsigargin. KBI cells stably expressing 5-
HT7(b) receptors were loaded with fura-2 for 20 min at room temperature, and 
direct cytosolic calcium measurements were carried out as described under 
Methods. The cells were treated with thapsigargin (1 µM) 30 seconds after the 
start of the recordings. The graph is composed of the average cytosolic 
calcium concentrations in 17 single cells in one experiment. The figure is a 
representative graph of three similar experiments.
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4.2.2   The role of PKA in the elevation of intracellular Ca2+ 
PKA has been shown to phosphorylate and thus activate ryanodine receptors and voltage-
gated calcium channels. Based on previous data we wanted to determine the role of PKA in 
the 5-HT induced increase in free intracellular calcium in HEK293 cells. As shown in fig. 
4.29, the previously observed elevation in cytosolic calcium concentrations wa completely 
abolished when the cells were preincubated with the PKA inhibitor H89. However, H89 
also eliminated the thapsigargin-induced increase in free cytosolic calcium (fig. 4.30). To 
our knowledge there is no published data supporting a role for PKA in the thapsigargin 
induced increase in free cytosolic calcium. 
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Figure 4.29   5-HT-induced elevation of free cytosolic calcium is abolished in the 
presence of H89. KBI cells stably expressing 5-HT7(b) receptors were loaded with fura-2 for 
20 min at room temperature, and direct cytosolic calcium measurements were carried out as 
described under Methods. The cells were pretreated with H89 (20 µM) for 20 minutes. 5-
HT (10 µM) was added after 30 seconds in the presence of 20 µM H89. The graph is 
composed of the average free cytosolic calcium concentrations in 25 single cells in one 
experiment. The figure is a representative graph of six similar experiments. 
Figure 4.30   Thapsigargin-induced elevation of cytosolic calcium is abolished in the 
presence of H89. KBI cells stably expressing 5-HT7(b) receptors were loaded with fura-2 for 
20 min at room temperature, and direct cytosolic calcium measurements were carried out as 
described under Methods. The cells were pretreated with H89 (20 µM) for 20 minutes. 
Thapsigargin (1 µM) was added after 30 seconds in the presence of 20 µM H89. The graph 
is composed of the average cytosolic calcium concentrations in 30 single cells in one 
experiment. The figure is a representative graph of three similar experiments. 
 64
5   Discussion 
5.1   Experimental Considerations 
5.1.1   Methodological limitations 
When evaluating the results presented in this thesis, it is important to bear in mind that the 
methods used to obtain these results have certain limitations. Each band on a Western blot 
represents proteins from the cells of one 35 mm well dish, and there are many handling 
steps involved before such bands are visualized. The quality of the cells and drugs, the 
variability in transfection rates, gel electrophoresis, transfer of proteins by Western blotting 
and attachment of primary and secondary antibodies to the membranes, are all factors that 
contribute to the reliability of the final outcome. It is reasonable to conclude that our results 
must be interpreted mainly as semi-quantitative, and the data must be assessed with 
caution. The bands on the membranes are evaluated visually in relation to the other bands 
on the same membrane, and in essence this consists in determining whether the bands have 
lower, similar or higher intensities. As expected, this makes it difficult to detect subtle 
changes, and bands on different membranes may generally not be compared to each other. 
It is possible to get a “quantitative” evaluation of the immunoassayed membranes by 
optical densitometric scanning, but as can be expected from the intrinsic variability in the 
results produced by our methods, this is not a very proficient way to assess the data, and 
may even produce artificial results. It is difficult, if not impossible to determine how to 
limit the scanned bands, and air bubbles, background noise and the appearance of the bands 
on a membrane may interfere significantly with the final numerical outcome. As such, 
optical densitometric scannings have not been conducted systematically in this thesis.  
   If not otherwise stated, most of the experiments have been conducted in duplicates and 
repeated at least three times.  
5.1.2   Receptor densities on the KB1 cells 
The KB1 cells is a clone of HEK293 cells stably transfected with 5-HT7(b) receptors and 
was made in our lab previously (courtesy of dr. K.A. Krobert). They exhibit fairly high 
receptor levels, 25000 fmol/mg protein, which may affect the data obtained with these cells. 
This is discussed further in chapter 5.2. 
5.1.3   Transfection 
Transfection is used to introduce plasmids into eukaryotic cells. Transfection rates are 
however, never 100%, and as a consequence, some cells remain without the desired 
plasmid, and thus do not express the protein it encodes. For example, in the case of 
cotransfection with dominant negative RasN17 and 5-HT receptors, the nontransfectecd 
cells may exhibit some activity of Ras, and thereby induce a basal phosphorylation of 
ERK1/2 which interferes with the final result. This basal activity is not, however, induced 
by stimulation with serotonin. On the other hand, there will always be a pool of endogenous 
proteins left, even in transfected cells. So although RasN17 disrupts signaling from Ras 
specific exchange factors to Raf-1, endogenous Ras may still functions normally and 
mediate phosphorylation of ERK1/2. 
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5.2   The Experiments – Activation of ERK1/2 
In this thesis, we report 5-HT-induced activation of ERK1/2 mediated through the human 
Gs-coupled serotonin receptors 5-HT7(b) and 5-HT7(d) transiently expressed in HEK293 
cells, and for the 5-HT7(b) receptors, in stably transfected HEK293 cells, the KB1 clone. 
   Most of the work was done with the 5-HT7(b) receptor and is part of an ongoing project in 
our lab where the human Gs-coupled serotonin receptors, 5-HT7 and 5-HT4 are investigated 
concurrently. Unless otherwise stated, the following discussion relates to the activation of 
ERK1/2 through 5-HT7(b) receptors in HEK293 cells. 
 
The main propagators of intracellular signals subsequent to stimulation of G-protein-
coupled receptors, are the Gα- and Gβγ-subunits of heterotrimeric G proteins. Gαs couples 
to and stimulates AC with subsequent elevation of cAMP. Cotransfection with hPDE4D2 
and 5-HT7(b) receptors almost completely abolishes ERK1/2 activation and demonstrates 
that this activation is largely dependent on cAMP. 
   Except for some ion channels, the two main targets for cAMP are PKA and Epac. Both 
PKA and Epac have been proposed to play a role in the activation of Rap1. However, Rap1 
is mainly activated through the Rap1 specific exchange factor Epac. We determined the 
role of Rap1 in the observed 5-HT-induced activation of ERK1/2 by cotransfecting 
HEK293 cells with the Rap1 specific GTPase activating protein Rap1GAP1 and 5-HT 
receptors. The observed 5-HT-induced activation of ERK1/2 in HEK293 cells was not 
influenced by co-expression of Rap1GAP1. In addition, stimulation with the Epac-specific 
cAMP analogue 8CPT-2Me-cAMP had no effect on ERK1/2 activation. Thus, in HEK293 
cells the Gs-coupled 5-HT7(b) receptors mediate phosphorylation of ERK1/2 through a 
Rap1-independent pathway, in contrast to the pathway reported for β2-ARs (21): Gs-AC-
cAMP-PKA-Rap1-B-Raf-MEK-ERK. 
   PKA has been shown to inhibit RTK-mediated activation of ERK1/2 in a cell type 
specific manner, and phosphorylation of Raf-1 is the main target for PKA-mediated 
regulation of the ERK1/2 cascade (45). Pretreatment of transiently transfected HEK293 
cells with H89 only sporadically and partially suppressed 5-HT-induced dual 
phosphorylation of ERK1/2. Cotransfection with the PKA inhibiting peptide PKI also 
produced similarly erratic results. However, the data considering the phosphorylation of 
Ras-GRF1 shed some light on this discrepancy. Residue Ser898 on Ras-GRF1 is a PKA-
specific phosphorylation site. It is anticipated that inhibition of PKA will interfere with this 
phosphorylation. In the experiments where H89 failed to interfere with activation of 
ERK1/2, it also failed to block phosphorylation on Ser898, and vice versa; in the 
experiments where H89 had an effect, both the phosphorylation of Ras-GRF1 and ERK1/2 
was inhibited. This indicates that PKA may play a role, but questions the effectiveness of 
H89 and the used PKI construct as inhibitors of PKA. In addition, the data obtained from 
direct cytosolic calcium measurements were also bewildering since H89 completely 
abolished thapsigargin-induced elevation of cytosolic calcium. To our knowledge there is 
no known role for PKA in thapsigargin induced elevation of free intracellular Ca2+ levels, 
and therefore, this discredits H89 further as a “selective, potent inhibitor of cAMP-
dependent protein kinase” as stated by the manufacturer (76). Davies et al. (77) has 
reported that H89 is not a selective PKA inhibitor, which is in agreement with our findings 
that H89 must be used with caution. We have hypothesized that combined treatment with 
fura-2 and H89 is too harsh on the cells, and merely kills them. This may explain the 
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dramatic effects of H89 on 5-HT- and thapsigargin-induced calcium elevation, and we are 
currently undertaking experiments to verify whether this is the case. 
   Currently we can not conclude from the data presented whether the 5-HT-induced 
phosphorylation of ERK1/2 through 5-HT7(b) receptors is mediated via a PKA-dependent 
pathway, but there are indications that activation of ERK1/2 through 5-HT7(b) receptors is at 
least partly dependent on PKA. 
 
An alternative pathway could have been mediated through the PI3-kinase, which has been 
shown to be activated by free Gβγ-subunits and to be a factor in the activation of ERK1/2 
in some cell systems. However, the PI3K inhibitor wortmannin did not interfere with 
ERK1/2 activation. These data suggest that PI3K does not play a role in the 
phosphorylation of ERK1/2 through 5-HT7(b) receptors. 
 
As for the 5-HT7(a) receptors, ERK1/2 activation through 5-HT7(b) and 5-HT7(d) receptors is 
dependent on the small G-protein Ras. The presence of the constitutively active mutant of 
Ras, RasV12 activated ERK1/2 strongly, whereas the dominant negative mutant of Ras, 
RasN17 almost completely abolished phosphorylation of ERK1/2. Phosphorylated ERK1/2 
levels were not, however, reduced entirely to basal levels with RasN17 and a possible 
explanation for this is discussed in chapter 5.1.3. Of course, it is also possible that other 
pathways are in action and constitute the remaining activation of ERK1/2. 
   Our main focus has been to elucidate how Ras becomes activated, and the majority of the 
work in this thesis has been dedicated to uncover a possible signal transduction mechanism 
leading from elevated levels of cAMP to activated GTP-bound Ras. 
 
Several studies have shown that the stimulation of 5-HT7 receptors leads to an increase in 
cytosolic calcium levels (65,67). Furthermore, calcium has been proposed to play an 
essential role in the activation of ERK1/2 for many receptor systems. We demonstrate that 
the concentration of free intracellular calcium is increased rapidly and transiently in KB1 
cells after stimulation with serotonin. This result, however, is somewhat dubious as it may 
be a result of receptor overexpression as mentioned in chapter 5.2.1. We know that the 5-
HT7(b) receptor density is very high in the KB1 cells, and it has been hypothesized that such 
a large receptor number may cause unspecific effects (78), e.g. coupling to other G 
proteins. This theory is supported by the appearance of the calcium influx curve which 
resembles that of a Gq coupled receptor (see chapter 5.1.2).  
   We further show that thapsigargin induces an elevation of intracellular calcium and 
mediates activation of ERK1/2. The calcium chelator BAPTA-AM interferes with ERK1/2 
activation mediated through 5-HT7(b) receptors, indicating that the availability of 
intracellular calcium is necessary for the proper activation of ERK1/2. The calcium channel 
blocker CAI also interfered with the observed ERK1/2 activation, indicating that functional 
calcium channels are required. The plasma membrane calcium channel blocker Gd3+ only 
interfered sporadically with ERK1/2 activation. We can only speculate over the reasons for 
this. One possibility could be that gadolinium ions have gained access to the cytoplasm of 
the cell in some experiments, and have thereby inhibited the intracellular calcium channels 
necessary for proper ERK1/2 activation. We found that Gd3+, in contrast to CAI, actually 
augmented thapsigargin-induced, as well as EGF-induced and basal non-stimulated 
ERK1/2 activation in several experiments. This may suggest that Gd3+, when restricted 
from access to intracellular calcium channels, actually prevents leakage of calcium from the 
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cell by blocking the plasma calcium channels, thus augmenting Ca2+-induced ERK1/2 
activation. CAI, which is known to cross plasma membranes, interfered strongly with 
thapsigargin-induced ERK1/2 activation but did not interfere with EGF-induced ERK1/2 
activation. These data indicate that CAI is able to block calcium channels without 
interfering with the classical Ca2+-independent RTK-Ras-Raf-MEK pathway.     
   Our data show that: i) ERK1/2 is activated by increased levels of intracellular calcium; ii) 
Stimulation of 5-HT7(b) receptors in HEK293 cells leads to increased levels of intracellular 
calcium; and iii) Treatment with either of two calcium inhibitors (BAPTA-AM and CAI) 
interferes with ERK1/2 activation through 5-HT7(b) receptors.  
   Taken together we propose that the observed activation of ERK1/2 through 5-HT7(b) 
receptors is mediated via a calcium-dependent pathway. We have not been able to 
determine from which reservoirs the observed increase in free intracellular calcium levels 
originates (intracellular/extracellular reservoirs, or a combination). Neither do we know 
how the influx of calcium is brought about. We have speculated that PKA may be involved, 
but the lack of molecular tools has so far hindered us from further investigation of this 
intriguing prospect. Pretreatment with H89 in the direct cytosolic calcium measurements 
caused a complete abolishment of calcium elevation subsequent to 5-HT stimulation, but as 
mentioned previously, these results are futile as H89 also eradicated thapsigargin-induced 
calcium elevation. 
   The nature of calcium signal transduction mechanisms is a very complex area of research. 
There are many receptor systems and regulators involved, and even the presence of the 
most specific inhibitors may result in numerous non-specific cellular effects as can be 
anticipated when interfering with such a crucial and fine-tuned second messenger. 
 
Ca2+/calmodulin activates the Ras specific exchange factor Ras-GRF1, which could be one 
of several exchange factors mediating activation of Ras subsequent to stimulation of 5-HT7 
receptors. We demonstrate that: i) Ras-GRF1 is expressed endogenously in HEK293 cells; 
ii) Ras-GRF1 is phosphorylated on the PKA specific site Ser898 following stimulation of 
5-HT7(b) receptors in HEK293 cells; iii) ERK1/2 is activated constitutively in HEK293 cells 
cotransfected with HA-Ras-GRF1-wt and 5-HT7(b) receptors, and this ERK1/2 activation is 
augmented even further after stimulation with 5-HT. 
   Calcium is a necessary component for the activation of Ras-GRF1 through binding of 
Ca2+/calmodulin. We have demonstrated that intracellular calcium is elevated in KB1 cells 
subsequent to stimulation with 5-HT, but we don’t know whether this calcium alone is 
sufficient to activate ERK1/2. The observed increase in free intracellular calcium is within 
an order of magnitude as that of thapsigargin, but the thapsigargin-response lasts much 
longer, which makes a direct comparison difficult. 
   We have not investigated the kinetics in these reactions, but the calcium levels peaked 
and declined rapidly. The onset was immediate and lasted from 30-60 seconds subsequent 
to 5-HT stimulation. However, activation of ERK1/2 peaked after 4-7.5 minutes. It can be 
envisioned that some of the calcium becomes bound to calmodulin after influx, and that 
Ca2+/CaM binds to and activates Ras-GRF1. However, the calmodulin antagonist W-7 
failed to inhibit ERK1/2 activation in our system. This may indicate that Ca2+/calmodulin is 
not necessary for the observed activation of ERK1/2. However, we have not obtained data 
confirming a positive effect of W-7 in the HEK293 cells. Experiments to confirm the 
activity of W-7 are currently being undertaken in our laboratory. If this finding is authentic, 
however, it weakens the Ras-GRF1-hypothesis considerably, but does not exclude a role for 
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Ras-GRF1, especially since we have demonstrated that over-expressed HA-Ras-GRF1-wt 
mediates activation of ERK1/2 and that this activation is augmented after 5-HT stimulation. 
 
The CaM kinase II is another effector of calmodulin thought to be able to mediate 
activation of ERK1/2 through many mechanisms, e.g. phosphorylation and activation of 
Raf-1 (75). However, KN-93, an inhibitor of CaMKII, did not interfere with ERK1/2 
activation suggesting that CaMKII does not play a role in ERK1/2 activation through 5-
HT7(b) receptors. 
 
Just as for PKA and Ca2+, the cell biology concerning calmodulin and CaMKII is very 
complex and involves a plethora of signal transduction mechanisms and localizations of 
substrates. A simplified example may illustrate this point: Apart from activating Ras-GRF1, 
Ca2+/Calmodulin also activates PDE1 (79) which lessens activation of ERK1/2 by reducing 
intracellular levels of cAMP. It is thus possible to envision that inhibition of calmodulin 
produces both negative and positive effects on ERK1/2 activation much the same way as 
PKA does, and this adds considerably to the complexity when investigating such signal 
transduction mechanisms. This is especially true in a situation where many separate 
pathways contribute to the final activation of ERK1/2, which might well be the case in our 
cell system. Taken together, the use of an inhibitor may result in an increase, decrease or no 
significant change in the activation of ERK1/2, depending on how essential the opposing 
mechanisms are. Of course, it is possible to construct such ad hoc propositions for all the 
data presented in this thesis if one were so inclined, and the point is that further evidence 
must be presented before final conclusions can be drawn. 
 
Several possible mediators of ERK1/2 activation were studied further. Especially 
interesting are the Src family kinases, which have been implicated in the activation of 
ERK1/2 through Gs-coupled receptors. Klinger et al. reported that elevation of cAMP in 
many cell systems caused an ERK1/2 phosphorylation which was inhibited by PP1, a Src 
kinase inhibitor (46). They did not report any data concerning HEK293 cells, but we found 
that the Src kinase inhibitor PP2 almost completely abolishes phosphorylation of ERK1/2 
through 5-HT7(b) receptors whereas the negative control (the inactive analog PP3) had no 
effect. This indicates that Src kinases play an important role in ERK1/2 activation.  
   The residue Tyr416 on Src is autophosphorylated when the Src kinases are activated, and 
can thus be used as a marker of Src activation. We have detected a basal level of Tyr416-
phosphorylated Src, but no increased phosphorylation on this conserved residue subsequent 
to stimulation of 5-HT7(b) receptors in HEK293 cells. Consequently, we do not have 
indications that Src kinases are activated in our system after treatment with 5-HT, but we 
have not investigated the kinetics of these reactions, and it could be that Src 
autophosphorylation of Tyr416 is a transient event which is difficult to detect. The cell 
biology of the Src kinases, as every other component of a cell, is subject to many control 
mechanisms. The Src family kinases may be phosphorylated on different residues, 
producing activation or inhibition. For example, it has also been proposed that PKA can 
phosphorylate and activate Csk, which in turn can phosphorylate and thereby inhibit Src 
family kinases (80). Our data show that inhibition of the Src family kinases reduces the 
activation of ERK1/2 through 5-HT7(b) receptors, but as of yet, we have not conducted any 
further experiments to clarify exactly how the Src family kinases contribute to ERK1/2 
activation. One can only speculate whether Src plays a direct or indirect role. It could be 
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that Src kinases are necessary for the overall metabolic apparatus in a cell, and disrupting 
them may thus decrease activation of ERK1/2 non-specifically. Needless to say, such a 
prospect needs further assessment. 
 
 
 
5.3   Future Research  
The role of PKA should be assessed further. Due to the fact that the available inhibitors 
exhibit several weaknesses as discussed in previous chapters, other strategies should be 
employed to disrupt PKA signaling. The use of siRNA-technology is promising in this 
regard and has been used with success to knock down PKA expression completely  (19). 
 
It is also of interest to explore further the role of calcium on ERK1/2 activation and the 
exact mechanism for how the 5-HT7 receptors mediate increase in free intracellular 
calcium. Direct cytosolic calcium experiments should be conducted with cell lines 
expressing lower receptor densities to verify the data from the KB1 clone. Various calcium 
inhibitors can be used to shed more light on how increased levels of intracellular calcium 
are brought about, for example L-type and T-type channel blockers (e.g. verapamil and 
mibefradil respectively) to determine whether voltage gated calcium channels contribute to 
calcium influx in HEK293 cells. It will be important to find out to what extent ryanodine 
receptors are involved in calcium influx, and inhibitors (ryanodine, procaine) and inducers 
(caffeine) of RyRs can be employed to shed more light on this. Moreover, the roles of 
calmoduline, CaM-kinases and Src family kinases must be studied further.  
   It is still unknown if and to what extent Ras-GRF1 contributes to the activation of Ras in 
our system. We have started screening for functional siRNA constructs to knock down Ras-
GRF1 expression to see whether this interferes with ERK1/2 activation.  
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5.4   Conclusions 
In conclusion, we demonstrate activation of ERK1/2 induced by 5-HT through the human 
Gs-coupled serotonin receptors 5-HT7(b) and 5-HT7(d) in HEK293 cells. The 5-HT7(b) 
receptor has been chosen as a model for further studies and the observed phosphorylation of 
ERK1/2 is cAMP- and Ras-dependent but Epac- and Rap1-independent. We show that 
stimulation of 5-HT7(b) receptors lead to a rapid but transient increase in intracellular 
calcium through an unknown mechanism, and that the observed activation of ERK1/2 is at 
least partly dependent on this increase in free intracellular calcium. We demonstrate that 
Ras-GRF1 is present endogenously in HEK293 cells and that it is phosphorylated on 
Ser898 subsequent to stimulation of 5-HT7(b) receptors, but its complete role in ERK1/2 
activation is still unknown. The role of the main effector of cAMP, PKA, remains elusive, 
but there are indications that activation of ERK1/2 through 5-HT7(b) receptors is at least 
partly dependent on PKA.  
 
Figure 5.1 gives a schematic representation of the possible signal transduction mechanisms 
leading from stimulation of the 5-HT7(b) receptors to the activation of ERK1/2 in HEK293 
cells. 
 
 
Figure 5.1   Possible molecular signal transduction pathways leading from  
the 5-HT7(b) receptor to activation of ERK1/2 in HEK293 cells. 
Question marks indicate areas of uncertainty that need further clarification. 
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7   Appendix 
7.1   Abbreviations 
Abbreviation Full name 
β-AR β-adrenergic receptor 
5-HT 5-hydroxytryptamine (serotonin) 
AC adenylyl cyclase 
ADP adenosine-5’-diphosphate 
AGS activator of G protein signaling 
AKAP A kinase anchor protein 
AMP adenosine-5’-monophosphate 
ATP adenosine-5’-triphosphate 
CalDAG-GEF calcium- and diacylglycerol regulated GEF 
CaM/CaMK calmodulin/calmodulin kinase 
cAMP adenosine-3’,5’-cyclic monophosphate 
cGMP guanosine-3’,5’-cyclic monophosphate 
CNS central nervous system 
CTx cholera toxin 
CREB cAMP response element-binding protein 
DAG 1,2-diacylglycerol 
DNA deoxyribonucelic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
Epac exchange protein directly activated by cAMP 
ERK extracellular signal-regulated kinase 
G-protein guanine nucleotide-binding protein 
GAP GTPase activating protein 
GDP guanosine-5’-diphosphate 
GEF guanine exchange factor 
GPCR G protein-coupled receptor 
Grb2 growth-factor receptor bound protein 2 
GRK G protein-coupled receptor kinase 
GTP guanosine-5’-triphosphate 
HEK293 human embryonic kidney 293 cell 
IP3 inositol triphosphate 
Jak Janus tyrosine kinase 
MAPK mitogen activated protein kinase 
MEK MAP and ERK kinase 
PDZ PSD–95 (postsynaptic density), Dgl (Discs–large),  
and ZO (zonula occludans) 
PI3K phosphoinositide 3-kinase 
PKA Protein kinase A (cAMP-dependent protein kinase) 
PKC Protein kinase C (Ca2+-dependent protein kinase) 
PLA2 Phospholipase A2 
PLC Phospholipase C 
PTx pertussis toxin 
Pyk2 Proline-rich tyrosine kinase 2 
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Rap1 Ras analogue protein 1 
Ras rat sarcoma 
RasGRF Ras guanine nucleotide releasing factor 
RasGRP Ras guanine nucleotide releasing protein 
RGS regulator of G protein signaling 
RNA ribonucleic acid 
RT room temperature (22ºC) 
RTK receptor tyrosine kinase 
SH2/SH3 Src homology 2 or 3 domain 
Shc SH2 domain containing 
SOS son of sevenless 
Src Sarcoma (v-Src – viral Src, c-Src – cellular (mammalian) Src) 
STAT signal transducers and activators of transcription 
TM transmembrane 
 
 
7.2   Materials and Recipes 
7.2.1   Chemicals and antibodies 
Chemical Abbreviation Manufacturer 
1-butanol, graded for analysis, min 99,5% butanol Merck 
5-hydroxytryptamine hydrochloride (serotonin) 5-HT Sigma 
Acrylamide 4K, ultrapure acrylamide AppliChem 
Agarose agarose Gibco 
Ammonium Persulfate APS Bio-Rad 
Ampicillin, sodium salt, min 98% ampicillin Sigma 
Bacto-Agar agar Difco 
Bacto-Tryptone tryptone Difco 
Bacto-Yeast extract yeast extract Difco 
BAPTA-AM BAPTA-AM Calbiochem 
BCA Protein Assay Reagent BCA-kit Pierce 
Bisacrylamide 4K, ultrapure bisacrylamide AppliChem 
Cryoprotective medium Cryoprotective medium BioWhittaker 
dimethylsulphoxide, sterile filtered DMSO Sigma 
Dulbecco’s Modified Eagles Medium, 4.5 g glucose/L DMEM Sigma 
Ethanol ethanol Arcus 
Epidermal growth factor EGF Sigma 
Ethidium bromide ethidium bromide Sigma 
Fetal bovine serum FBS Gibco 
Fura-2-AM Fura-2-AM TefLabs 
Gadolinium (III) chloride hexahydrate 99% gadolinium Sigma 
Glycin 99.8% glycin AppliChem 
H89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide dihydrochloride) 
H89 Sigma 
Hank’s balanced salt solution, 1x w/phenol red HBSS BioWhittaker 
Hydrocholoric acid 37%, p.a. HCl Merck 
KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-
methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-
N-methylbenzylamine)) 
KN-93 Calbiochem 
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L-651582 (carboxyamidotriazole) CAI McKesson 
Lipofectamine 2000 lipofectamine 200 Invitrogen 
Lipofectamine reagent lipofectamine Invitrogen 
Methanol, p.a. methanol PROLABO 
N’,N’,N’,N’-tetra-metyl-ethylene-diamide TMED AppliChem 
Non-fat dry milk dry milk Nestle 
Optimem optimem Gibco 
Phosphate buffered saline, 10x powder, ultrapure grade PBS Amresco 
Pluronic acid pluronic acid Sigma 
PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-
d]pyrimidine) 
PP2 Calbiochem 
PP3 (4-Amino-7-phenylpyrazol[3,4-d]pyrimidine) PP3 Calbiochem 
QIAGEN Plasmid Maxi Kit QIAGEN maxiprep QIAGEN 
SOC-medium SOC-medium Gibco 
Sodium Chloride, min 99% NaCl Sigma 
Sodium dodecyl sulphate, ultrapure, min 99.5% SDS Gibco 
Sodium hydroxide NaOH Merck 
Sodium-ortho-vanadate Na3VO4 Sigma 
SuperSignal West Dura Extended Duration Substrate SuperSignal Pierce 
Thapsigargin thapsigargin Calbiochem 
TOP-10 Chemically competent E.coli cells TOP-10 cells Invitrogen 
Trizma base min 99.9% 
(Tris[hydroxymethyl]aminomethane)  
tris base Sigma 
Trizma hydrochloride min 99% 
(Tris[hydroxymethyl]aminomethane hydrochloride) 
tris-HCl Sigma 
Trypsin/Versene EDTA 0.5g/L trypsin BioWhittaker 
Tween-20 tween Bio-Rad 
Ultraculture general purpose serum free medium Ultraculture BioWhittaker 
W-7 (N-(6-Aminohexyl)-5-chloro-1-
naphthalenesulfonamide hydrochloride) 
W-7 Sigma 
Wortmannin wortmannin Sigma 
β-mercaptoethanol, min 98% β-mercaptoethanol Sigma 
 
 
 
Antibody Species Manufacturer/prod.number 
Anti-phospho-p44/42 MAP Kinase  Mouse Cell signaling (#9106L) 
Anti-MAP-kinase 1/2 (ERK 1/2-CT) Rabbit Upstate biotecnology (06-182) 
Anti-mouse IgG HRP linked Sheep Amersham biosciences (NXA931) 
Anti-rabbit IgG HRP linked7 Donkey Amersham biosciences (NA934) 
Anti-phospho-Ras-GRF1 (Ser916) Rabbit Cell signaling (#3321) 
Anti-Ras-GRF1 (c-20)  Rabbit Santa Cruz biotechnology (sc-224) 
Anti-phospho-Src (Tyr416) Rabbit Cell signaling (#2101) 
Anti-Src Mouse Oncogene (#OP07) 
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7.2.1.1   Contents of commercial kits 
QIAGEN Plasmid Maxi Kit 
Buffer P1 (Resuspension)  
50 mM Tris-Cl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
 
Buffer QBT (Equilibration)  
750 mM NaCl 
50 mM MOPS pH 7.0 
15% isopropanol 
 
Buffer P2 (Lysis)   
200 mM NaOH 
1% SDS 
 
Buffer QC (Wash)   
1.0 M NaCl 
50 mM MOPS pH 7.0 
15% isopropanol 
 
Buffer P3 (Neutralization)  
3.0 M potassium acetate pH 5.5 
 
Buffer QF (Elution)   
1.25 M NaCl 
50 mM Tris-Cl pH 8.5 
15% isopropanol 
 
 
7.2.2   Solutions and buffers 
7.2.2.1   Amplification of DNA plasmids 
TE Buffer    
10 mM Tris-Cl pH 8.0 
1 mM EDTA 
 
LB Medium    
10 g tryptone 
5 g yeast extract 
10 g NaCl 
ad 1000 ml H20 
pH 7.0 
Autoclave 
 
 
7.2.2.2   Direct cytosolic calcium measurements 
Hepes buffer 
10 mM Hepes 
1.2 mM Ca2+ 
pH 7.37 
288 mOsm 
Fura-2-AM Loading Buffer 
50 µg Fura-2-AM (50 nmol) is thawed  
for 30 minutes protected from light 
and dissolved in 30 µl DMSO/Pluronic acid (10 % solution), 
and kept dark for 30 minutes. 
The Fura-2-AM stock solution is diluted 
in 10 ml Hepes buffer (5 µM Fura-2-AM) 
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7.2.2.3   SDS-PAGE and Western blotting 
Harvest solution  
35 mM SDS 
1 mM Na3VO4 
50 mM Tris pH 7.4 
 
 
1.5 M Tris-base pH = 8.8 
181.71 g Tris-base 
900 ml dH20 
Adjust pH to 8.8 with conc HCl at RT 
ad 1000 ml dH20 
Stored at RT 
1.0 M Tris-base pH = 6.8 
60.57 g Tris-base 
400 ml dH20 
Adjust pH to 6.8 with conc HCl at RT. 
ad 500 ml dH20 
Stored at RT 
 
30% Acrylamidemix  
4.08 M Acrylamide 
64.86 mM N,N’-methylenebisacrylamide 
stored in dark bottle up to 4 weeks at RT 
 
4x Loading Buffer (for loading samples) 
12.5 ml 1.0 M Tris-HCl pH = 6.8 
40 ml 10% SDS 
40 ml glycerol 99% 
0.4 ml bromophenol blue 
ad 100 ml dH20 
Activate with 10% β-mercaptoethanol 
Stored at RT. 
 
10 ml 10% polyacrylamide gel  
(ERK1/2 assay) 
4 ml dH20 
3.3 ml 30% acrylamide 
2.5 ml 1.5 M Tris-base pH 8.8 
100 µl 10% SDS 
100 µl 10% APS (fresh) 
4 µl TEMED 
 
5x Running buffer  
(for SDS-PAGE) 
124.65 mM Tris-base 
1.24 M g glycine 
17.34 mM SDS 
Stored at RT 
10 ml 6% polyacrylamide gel (Ras-GRF1 
assay) 
5,3 ml dH20 
2 ml 30% acrylamide 
2.5 ml 1.5 M Tris-base pH 8.8 
100 µl 10% SDS 
100 µl 10% APS (fresh) 
8 µl TEMED 
 
10x Transfer buffer  
(for Western blotting) 
312.86 mM Tris-base 
2.4 M glycine 
Stored at RT 
3 ml 5% polyacrylamide gel  
(stacking gel) 
2 ml dH20 
0.5 ml 30% acrylamide 
0.375 ml 1.0 M Tris-base pH 6.8 
30 µl 10% SDS 
30 µl 10% APS (fresh) 
2 µl TEMED 
 
700 ml blotting buffer  
(for each Western blotting chamber) 
70 ml 10x Transfer buffer 
490 ml dH20 
140 ml methanol 
Stored at 4ºC 
 
